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ABSTRACT 
Identification of Activation of Transcription Factors from Microarray Data 
Andrei Kossenkov 
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Signaling pathways play a critical role in cell survival and development by 
regulation of transcription factor activity causing necessary gene products to be 
produced in response to different stimuli. Although the task of detecting activities of 
signaling pathways is extremely difficult, recent advances in microarray technology 
promise progress in the field. There are many clustering and pattern recognition 
algorithms that have been applied to analysis of microarray data. However, these 
methods lack an ability to address the biological nature of the data and force 
assignment of one gene to a single co-expression group, while ignoring the fact that 
many individual genes are regulated by different signaling pathways in response to 
different stimuli, and therefore the genes should be assigned to multiple groups of co-
expression. Another issue in microarray analysis is a low signal-to-noise ratio 
provided by the technology, yet most of the clustering methods do not even take 
errors of the measurements into consideration. 
Bayesian Decomposition is an algorithm that decomposes microarray data 
into a set of biologically meaningful expression patterns that could be linked to 
certain signaling pathways and groups of genes that contain these patterns, allowing 
assignment of one gene to multiple patterns of expression. To address the problem of 
low signal-to-noise we modified the Bayesian Decomposition algorithm to allow 
inclusion of prior gene coregulation information to improve statistical power. We also 
created the Automated Sequence Annotation Pipeline to provide microarray data 
mining processes with annotation information at all steps and particularly to deduce 
the coregulation information for a given set of genes from transcription factor 
database TRANSFAC. 
 xii
We validated enhancements done to Bayesian Decomposition on simulated and real 
biological data and showed that using coregulation information can improve ability of 
the method to recover correct results. The designed data mining process that uses the 
Automated Sequence Annotation Pipeline and the modified Bayesian Decomposition 
was applied to determine transcription factor activities linked to patient outcome in 
gastrointestinal stromal tumor (GIST) patients undergoing treatment with imatinib 
mesylate (IM, Gleevec). The study demonstrates genes that can be potentially used as 
biomarkers to predict GIST patient response to Gleevec treatment and activity of 
transcription factors that can contribute to difference in the response. 
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CHAPTER 1: INTRODUCTION 
1.1 Cancer biology 
 Cancer is a leading cause of death around the world, resulting in over 6 
million deaths per year. Cancer is caused by a series of events that transform a normal 
cell into abnormal, so that it grows and divides uncontrollably. There are three 
defined steps of the transformation process: initiation, promotion and progression [1] 
(Figure 1). The initiation step is characterized by DNA mutation due to various 
factors such as viruses [2] or environmental damage (air pollution [3], tobacco 
consumption [4], radiation [5], chemical carcinogens [6], etc.). Promotion refers to 
process of growth and proliferation of the initial mutated cell that results in a small 
tumor, which in the progression stage undergoes further growth and invades the 
tissue of origin, accompanied by morphological changes. Sometimes progression 
develops into metastasis, when cancer cells acquire an ability to travel through the 
blood stream to other tissues of organism. 
 
 
Initiation Promotion Progression
 
Figure 1. Initiation, Promotion and Progression stages of cancer development. DNA damage of one of normal 
cells (Initiation) result in uncontrolled growth and proliferation of the initial cell (Promotion) with following 
further growth and invasion of tissue of origin. 
 
 
 
 Upon detection, a cancer phenotype reflects mutations that occurred at the 
initiation stage and mutations that accumulated during abnormal cell development. 
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When coupled with genetic heterogeneity between patients, the result is a disease of 
great complexity and heterogeneity that produces different tumor progression rates, 
drug responses, and outcomes across patients. Therefore, one of the most important 
tasks in cancer research is to identify the specific genetic variations for an individual 
cancer that lead to the specific cancer phenotype. Although very heterogeneous at 
later stages, resulting in expression level changes of thousands of genes as 
documented by multiple studies of transcriptional profiling [7-10], cancer may be the 
result of very few genetic changes [11, 12], giving opportunity to understand precise 
mechanisms of the disease. 
1.2 Signalling pathways and Cancer 
In order to survive and develop normally, cells must react properly to various 
changes in their environment and their internal state. Varying environmental 
conditions will result in different cell reactions that require activity of specific 
proteins to perform necessary functions to adapt the cell to these conditions. One of 
the ways to get required proteins is to transduce a signal received from the 
environment through a pathway to activate transcription factors that initiate 
transcription of target genes. Such signaling pathways are highly controlled, so that a 
cell can provide a precise response to a certain stimulus. At the same time there are 
multiple pathways activated at the same time and connected with each other forming 
signaling networks. This makes a cell a very complicated system with elaborate 
control and repair mechanisms evolved to be stable, although sometimes because of 
accumulated mutations or under extreme conditions, signaling pathways may loose 
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appropriate regulation, which can lead to cancer, diabetes and many other disease 
states. 
One of the most studied intracellular signaling pathways are the 
phosphorylation cascades that transduce signal through activation of mitogen-
activated protein kinases (MAPKs). MAPK cascades play a key role in various 
important cellular processes, including response to external stimuli, growth, 
proliferation, differentiation and apoptosis. There are three major MAPK families in 
eukaryotic cells, including extracellular-signal regulated kinase (ERK, also known as 
p42/44 MAP kinase), JUN N-terminal kinase (JNK, also known as SAPK1) and p38 
(also known as SAPK2) [13-16]. More specifically, ERK cascade is known to 
regulate cellular proliferation, differentiation, and survival, JNK pathway is related to 
stress response and apoptosis, and p38 also mediates response to environmental stress 
and is involved in other fundamental biological processes. 
MAPKs cascades are activated by a variety of receptors leading to signal 
transduction through intermediate proteins and represent a complex network of 
consequent protein activations where different parts of the network are connected 
between each other to keep the system in balance. For example, crosstalk between 
RAS/RAF/MEK/ERK proliferation cascade and PI3K/AKT apoptosis related 
pathway represent fine-tuned balance to keep a cell under control [17]. 
Over the last few decades numerous signal transduction pathways have been 
reported whose dysregulation may play an important role in the growth and survival 
of cancer cells [18-22]. Signaling cascades can be distorted at different levels, starting 
from constitutive activation of tyrosine kinase receptors, further downstream 
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mutations of signaling genes or mutations of transcription factors, resulting in 
uncontrolled changes of transcription of genes that involve cell division, cell growth 
and survival that can lead to tumor development. For example, epidermal growth 
factor receptors (EGFR) activate survival signaling pathways including PI3K/AKT, 
RAS/RAF/MEK/ERK, and JAK/STAT signaling pathways (Figure 2). A number of 
cancers including breast and brain tumors [20, 23] show overexpression of epidermal 
growth factor receptors, causing undesirable cell proliferation as a response to smaller 
amounts of epidermal growth factor. Mutations in Ras proteins can imitate growth-
promoting guanidine triphosphate (GTP)-bound Ras leading to downstream 
activation of the MAPK cascade leading to cell proliferation [24].  
Pathway dysregulation can be determined by measuring gene expressions 
changes and recent advances in microarray technology allow measurement of  mRNA 
expression levels for thousands genes simultaneously [25, 26]. Due to complicated 
processes of transcription, translation and protein activation, it is impossible to use 
these measurements of mRNA levels as upstream indicators of protein activity [27, 
28]. Specifically, study of a subset of genes expressed in the Saccharomyces 
cerevisiae showed a low correlation of 0.356 for 73 selected genes between mRNA 
and protein expression levels [28]. While true for the yeast species, the complexity of 
mammalian systems contribute even more to the difference. Protein activation is yet 
another stage of regulation process that determine amount of functioning proteins in a 
cell and that is especially true for signaling proteins, which require post-translational 
modification to become active. As such, gene expression can be treated only as a 
downstream indicator of pathway activity. 
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Figure 2. Part of epidermal growth factor (EGF) pathway. 
EGF receptor (EGFR) transduces signal from EGF to RAS/RAF/MEK/ERK, PI3K/AKT and 
JAK/STAT pathways, that activate transcription factors related to cell survival and proliferation. 
Transcription factor STAT3 induces progression through the cell cycle and prevents apoptosis, NF-κB 
– regulates expression of anti-apoptotic genes, and ELK-1 – mediates growth factor stimulation of 
proliferative response. 
 
 
 
1.3 Gastrointestinal Stromal Tumors 
Gastrointestinal stromal tumors (GISTs) are rare but deadly mesenchymal 
tumors affecting approximately 2,000 people in the U.S. per year.  GISTs are the 
most common gastrointestinal mesenchymal malignancies and may occur anywhere 
along the gastrointestinal tract, but most often occur in the stomach and small 
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intestine, representing 60%- 70% and 20%-30% of tumors, respectively [29].  GISTs 
are discovered either incidentally during endoscopic, radiologic, or surgical 
procedures; or are diagnosed in the evaluation of patients with an abdominal mass, 
abdominal pain, or upper gastrointestinal bleeding.  Complete surgical resection is 
still the only treatment that can completely cure the disease. However, even for 
patients whose tumors are fully removed 5-year overall survival is only 50%, use of 
chemotherapy and local radiotherapy appeared ineffective in patients with 
unresectable or metastatic GISTs, which represent 30% of tumors, giving a median 
survival ranging from 9 to 20 months [30, 31]. 
GISTs are considered to originate from the interstitial cells of Cajal (ICC) [31, 
32], since they share many of the phenotypic features. Experiments show that 90%-
95% of GISTs have c-KIT gain-of-function mutations, mostly in exon 11 but also in 
exon 9,13, or 17 [33, 34], while the other cases have gain-of-function mutations in the 
platelet-derived growth factor receptor alpha [35]. The mutations of KIT occur 
somatically and lead to constitutive, ligand independent activation of KIT and its 
signal transduction pathways, such as the PI3K/AKT and RAS/RAF/MEK/ERK 
pathways, and probably the STAT3 pathway [36]. 
 Gleevec (imatinib mesylate, STI-571; Novartis, Basel, Switzerland), a 
derivative of 2-phenylaminopyrimidine, is a small molecule with activity against a 
number of related protein tyrosine kinases, including KIT, PDGFR, ABL and BCR-
ABL [37-40]. In a nation-wide phase II clinical trial more than 81% of patients with 
unresectable or metastatic GIST benefited from Gleevec therapy; 53.7% had a partial 
response and 27.9% achieved stable disease [41].   
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 While a significant success in treatments of GISTs with Gleevec was shown 
lately, there is still a little understanding of cases with no or poor response to the 
treatment. Some mechanisms suggested for such resistance included secondary point 
mutations of KIT or PDGFR [42, 43] or activation of alternate receptor tyrosine 
kinase protein [44], but overall picture is still unclear and requires additional research 
efforts. An ongoing multi-institutional clinical trial performed through the 
cooperative group of Dana-Farber Cancer Institute, Oregon Health Sciences 
University, Fox Chase Cancer Center and University Hospital of Helsinki focuses on 
the problem and is generating microarray measurements on biopsies from GIST 
patients before and surgical samples after Gleevec treatment. We have applied a 
modified version of the Bayesian Decomposition algorithm [45] to analyze the data in 
order to link patients’ response to treatment to changes in signaling pathways and 
understand conditions leading to non-response to Gleevec. 
1.4 Microarrays 
First high-throughput gene expression microarrays used radioactively labelled 
targets hybridized onto cDNA probes grown on membrane-based arrays [46]. This 
then developed into microarrays that use fluorescent labeling to avoid problems with 
stability, handling, disposal and safety risk of radioactive compounds. First 
introduced in 1995 [26], hybridization of fluorescently labeled targets to cDNA 
microarrays printed on glass targeted 46 cDNA probes simultaneously and already by 
the end of 1996 cDNA chips with 1,000 probes were reported to be used in 
experiments [47, 48]. Since then rapid growth in the technology allowed millions of 
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probes to fit on a 1.28 cm2 chip (CeneChip expression arrays from Affymetrix), 
enough to cover whole genome of an organism. 
While various microarray systems use different chip printing processes, the two 
most important chip types are one-channel arrays (Affymetrix) – in situ synthesized 
oligonucleotide arrays that use single fluorescence channel to measure expression 
level of genes of a sample  that build up oligos directly on a slide, and two-channel 
arrays (spotted arrays) made by depositing pre-made oligos or cDNAs onto slides and 
two fluorescence are used to label experiment and control samples before 
hybridization.  
 In order to measure expression levels of genes, messenger RNA (mRNA) 
from sample of interest is extracted, converted to complimentary DNA (cDNA) or 
complimentary RNA (cRNA) and tagged with a fluorescence label that can be 
detected with a scanning device at a certain wavelength. For two-channel arrays 
reference mRNA is also required to be prepared and tagged with a different 
fluorescence label. Then dyed products are hybridized on a microarray slide, excess 
labelled oligonucleotides are washed off and the microarray is scanned. The whole 
experimental process is schematically shown in  
Figure 3. Although these two approaches are very different in design, recent studies 
suggest that both methods are essentially equivalent when compared on controlled 
data [49]. 
 
 
 
 9
SAMPLE REFERENCESAMPLE
Biotin
label
Hybridization
One-channel
microarray
Two-channel
microarray
Labeling
Cy3/Cy5
labels
mRNA isolation
Scanning
Single 
hybridization
Competitive 
hybridization
 
Figure 3. Schematics of experimental process using one-channel and two-channel microarrays. 
 
 
 
Microarray technology is a very powerful tool for molecular biology, but it 
has certain drawbacks that limit the effectiveness of microarray experiments. First, 
biological variations, artifacts of preparing samples for analysis, inconsistencies of 
array chip printings, all contribute to low signal-to-noise in microarray technology, 
which frequently results in inconsistent results.  The impact from the problem can be 
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lowered by performing replicate experiments and using analysis methods that can 
take into account the estimated noise of the system. Another issue, as mentioned 
earlier, is that measurements of mRNA levels can not be used as a direct indicator of 
corresponding protein activity due to complicated multi-step post-translational 
modifications. Although it limits the interpretation of microarray results, it is still 
possible to use changes in expression levels as downstream indicators of biological 
processes of the cell. 
Correct gene assignments and other related annotations are also of great 
importance for analysis and result interpretation of microarray data. Improper probe 
annotations can be a result of various uncertainties. Mismatches of clones from 
cDNA libraries used for spotted microarray construction can produce a significant 
amount of errors in identifications for these probes. In fact, a study of commercial 
subset of the IMAGE Consortium mouse cDNA clone collection showed that only 
62.2% of 1189 analyzed stocks were correctly identified [50]. Another example is a 
work of Harbig et al. who re-identified the probesets on the Affymetrix U133 plus 2.0 
GeneChip array that resulted in redefinition of approximately 37% of the probes [51]. 
Non-specificity of probes to splice variants and overlapping transcripts that is 
sometimes ignored due to limited knowledge can be another reason for annotation 
error. Also, there are many mistakes in clustering of Expressed Sequence Tags (EST), 
which frequently were used in older platforms to design microarray probes to target 
specific genes, resulting in false assignment of EST to certain gene. More recent 
arrays are designed against the genome, but annotations of the GenBank genomic 
accession numbers are imperfect, and although many errors are corrected constantly, 
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it is clear that there are still inconsistencies in current assignments of microarray 
probes that can significantly affect results of experiment. Therefore, an ability to 
acquire the most recent annotation information is crucial for receiving correct results.  
1.5 Microarray data analysis  
 Prior to microarray data analysis, several pre-processing steps are required. 
First, scanned images are quantified to determine the signal intensity of each spot. 
This is usually done by software specifically designed for a specific microarray 
platform that the experiment was performed on, although there are some other 
alternative quantification methods and their modifications available, especially for 
spotted arrays, e.g. GenePix [52], ImaGene [53], TIGR Spotfinder [54], WaveRead 
[55], and many more [56]. Second, normalization of microarray data is performed to 
remove dye-related differences between two channels and various slide-specific 
artifacts that can exist between different microarray. After pre-processing, the 
normalized microarray data can be analyzed using statistical methods, clustering 
techniques or more advanced pattern recognition approaches. 
1.5.1. Normalization 
 When performing experiments with multiple microarray slides, there are 
always sources of non-biological variation between arrays such as dye biases, sample 
preparation or hybridization differences, scanner calibrations, slide printing 
variations, volume of initial RNA, etc. To correct some of this variability, a series of 
steps referred to as “data normalization” are performed on the data before analysis. 
While the main assumption behind normalization of microarray data is that most of 
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the genes on the slide do not change their expression levels and numbers of up- and 
down-regulated genes on the array are roughly equal, most methods try to adjust 
expression levels of the genes, so overall average expression remains the same across 
different arrays. Additional steps can include removing saturated signals from 
microarray, background correction, low expression genes correction, etc. 
 For two-channel microarrays, many different methods have been developed in 
order to compensate for dye-effects and other systematic errors between arrays. Total 
intensity normalization [57], for example, transforms expression ratios between 
channels in such a way that mean log2(ratio) across all measurements of the array is 
equal to zero. There are other methods that use similar global normalization 
approach, including log centering, rank invariant methods [58], and many other 
variations. While such methods do not take into account situations when dye-effects 
depend on signal intensity and/or spatial location within the array [59], locally 
weighted linear regression (LOWESS) method [60] accounts for such effects and has 
been proven to be a robust, powerful normalization method for different types of two 
color microarray experiments [59]. Although many new methods [61-64] and 
modifications [65, 66] have been proposed and compared to LOWESS, the 
comparison results are inconsistent and new methods outperform LOWESS only in 
special cases [67]. 
 Affymetrix arrays, designed to measure abundance of mRNA levels using 
only one channel, require different approaches to normalize the data. There are 
several widely used methods developed for expression data. Microarray Suite (MAS) 
from Affymetrix uses a linear regression method for perfect match (PM) values [68]. 
 13
Introduced later, dChip software uses a model-based expression index (MBEI), with a 
chip showing median intensity selected as a baseline array, an invariant set of probes 
used for comparison between two samples, and a non-parametric curve (running 
median) is fitted through the data points [69]. The most recently developed method, 
robust multi chip average (RMA) use quantile normalization, where highest PM 
intensities (background corrected and log transformed) are replaced  by their average 
and the process is repeated for all intensities in descending order [70]. A modified 
version of RMA, GCRMA has been developed to account for GC rich probes having 
higher intensities due to increased binding, and models probe intensity as a function 
of GC content of the probe [71]. 
1.5.2. Statistical methods 
Fold change (FC) was one of first methods used to identify genes that are 
differentially regulated between two conditions (samples, time points, etc.) by 
selecting genes with fold change (ratio of the measured response in one condition to 
that in another) that is outside of a given cutoff. Although very popular from when 
microarrays were first introduced due to its simplicity, the method has major 
drawbacks and has been called into question [72-75]. The inability to incorporate 
variance, provide confidence intervals for results, and potential high false discovery 
rate (FDR) of the method resulted in attempts to develop and apply more stringent 
statistical approaches. 
In order to assign some level of confidence to inference that a gene is 
differentially expressed between conditions, various statistical methods were 
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suggested for microarray analysis, among which Student’s t-test, Mann-Whitney-
Wilcoxon rank test, analysis of variance (ANOVA) and significance analysis of 
microarray (SAM) are among most popular methods. ANOVA uses Fisher’s F-
distribution as part of the test of statistical significance and compares group variations 
to the overall variation observed [76]. There are variations of ANOVA analysis, 
including one-way, factorial or non-parametric ANOVA, that are used depending on 
experimental design or hypothesis an investigator wants to test [77, 78]. Student’s t-
test is used to test the hypothesis that a gene’s expression levels differ between two 
sets of samples by using the T statistic and determining the significance level of the 
difference from t distribution [79]. SAM test uses slightly different statistic that is 
based on t-statistic, but also uses a correction [80] that reduces the relative differences 
for low expressed genes and genes with similar expression levels. A permutation 
procedure is also used to estimate the false discovery rate for the final results [80].  
Mann-Whitney-Wilcoxon rank test is a non-parametric statistical test, that like a t-test 
and SAM, compares for each gene the difference between measurements in two 
groups. However, it does not require assumptions about the form of the distributions 
of the measurements, so it is more reliable when used on microarray data with large 
number of outliers or high noise. The method’s statistical power strictly depends on 
sample sizes, and provides poor significance levels for groups with fewer than 6 
samples. 
Using simple statistical approaches to test thousands transcripts in one 
experiments is likely to result in many false positive results with significant 
confidence level. While the significance of confidence levels are usually depend of 
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the statistical test performed on the data, a proper adjustments are required to 
compensate for large number of tested genes or for small number of samples [81, 82]. 
On the other hand, experiments with a low number of samples usually do not have 
enough statistical power to produce significant results. While performing tests based 
on gene-by-gene calculations is inefficient, it is possible to ‘borrow’ information 
across genes from microarrays to improve statistical power of the results, as 
clustering and pattern recognition methods do when combine genes together based on 
their expression profiles.  
1.5.3. Cluster analysis 
Cells have evolved to survive by reacting to different internal and external 
environmental conditions with a response that results in activating a set of proteins 
required to use or oppose these conditions. To optimize the process, genes whose 
products function together are usually undergoing same regulatory mechanisms so 
they are coordinately expressed in response to stimuli. This property is used by many 
clustering methods that group genes together based on their expression profiles and 
associate such groups of transcripts with a biological function or biological process 
that they are involved in. In this case microarray data for analysis with clustering 
methods can be represented by a matrix with measurements of genes (rows) for 
multiple conditions (columns), where conditions can be of various kinds of samples, 
e.g. different treatments, time points, patients, etc.  
There are many widely used clustering algorithms for analysis of microarray 
data,  including hierarchical clustering [83], quality threshold clustering [84], k-means 
 16
clustering [85], and self-organizing maps [86], among many other methods reviewed 
elsewhere [87, 88]. These methods differ from each other considerably and lead often 
to different results, even within the same method when using different distance metric 
as a measure of similarity between genes. 
Clustering is a common technique widely used in many fields and various 
methods were borrowed and adopted for microarray analysis. Hierarchical clustering 
is one of the first clustering algorithms applied to microarray data [83, 89-92]. Using 
a distance metric (Eisen’s original metric [83]), the method builds a hierarchical 
binary tree (called a dendrogram), starting from the individual genes’ expression 
profiles as leaves (also thought of as separate clusters) by progressively merging 
clusters, where each internal node represents the average of its two children. The 
constructed tree can be cut at some point according to a threshold value to receive 
clusters of required characteristics.  Due to its simplicity and clear representation, 
hierarchical clustering has been used in many reported microarray experiments, but a 
number of drawbacks should be considered. First, hierarchical clustering is a greedy 
search algorithm, meaning that merging decisions on early steps are based only on the 
distance between nodes and cannot be undone, but not necessarily the best ones in 
global scale and can lead to mistakes in the overall clustering. Second, dendrograms 
and corresponding heatmaps, which used extensively in visualizations of the analysis 
results, suffer from inversion problems that complicate interpretation of the hierarchy 
[93]. In addition, complexity of dendrograms for larger data sets makes them difficult 
to understand, and the choice of location for tree cut to receive final clusters is 
unclear. And finally, analysis of yeast cell-cycle dataset with hierarchical clustering 
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performed by Cherepinsky et al. showed that the method has very low accuracy of 
gene assignments to clusters (less than 60%) [94].  
The k-means clustering starts from randomly dividing genes into k groups and 
calculating cluster centers (or centroids) for each of these groups. New groups are 
formed by reassigning each gene to the closest centroid. Then the centroids are 
recalculated for the new clusters and the process repeats [95]. While simplicity and 
speed of the method are the main advantages of the method, the most important 
disadvantage is that results are not unique across different runs and depend on starting 
positions of centroids. Another obstacle for analysis of microarray data is unknown 
number of clusters prior to analysis that needs to be estimated somehow.   
The quality threshold clustering algorithm (QT Clust) is more 
computationally intensive than hierarchical or k-means clustering, but does not 
require specifying the number of clusters prior to analysis and always returns the 
same result for each run [84]. The algorithm iterates as follows. A maximum diameter 
for clusters is chosen before the analysis, and a candidate cluster is formed by first 
gene data point. Other data points are iteratively added by including the closest, based 
on jackknife correlation [84], point until no data points can be added to the cluster 
without surpassing the diameter threshold. Next candidate cluster is formed by 
second gene data point and all other data points, including those from first cluster, are 
considered for the cluster. The process repeats for all genes of the analysis. At first 
step, the number of clusters equal to the number of genes, and the largest candidate 
cluster is set as a real cluster, whereas all the genes from this cluster are removed for 
further analysis. The method recurses by analyzing remaining set of genes. As 
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mentioned earlier, the method does not require a number of clusters prior to analysis. 
However, a threshold for cluster diameter is required and hard to estimate. Although 
there was an attempt to improve algorithm by estimating appropriate threshold from 
the data itself [96], the problem of setting different diameter threshold for different 
clusters is not resolved.  
The method of self-organizing maps (SOM) performs the following 
procedure. After choosing an initial grid of nodes (usually one- or two-dimensional), 
the nodes are mapped randomly into k-dimensional space. At each step of the 
algorithm a random data point is chosen and nodes are moved in the direction of it. 
Nodes are moved depending on distance between a node and that data point, so the 
closest node is moved the most compared to more distant nodes. After a number of 
such iterations, nodes represent clusters, with neighbor nodes in initial grids defining 
related clusters. Although a number of successful application of SOMs have been 
reported [86, 97-100], several disadvantages exist for the method. Sensitivity of SOM 
to incomplete data is a problem that is very important in microarray data analysis, due 
to abundance of missing data points resulting from data flagging during 
preprocessing. Also, a SOM can yield different decompositions of the data depending 
on the choice of initial conditions. Another issue is that initial node grid is fixed and 
may not be changed during the analysis, and that can lead to inappropriate mapping 
of the data space. In addition, when two data points are mapped from high 
dimensional space to nearby locations on the two dimensional grid, it is possible that 
those points are actually far apart in the higher dimensional space.  
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These methods have been used for the majority of published microarray 
studies, but all of them have a disadvantage of forcing one gene into single co-
expression cluster, when many individual genes are involved in more than one 
process of the cell and therefore co-express in multiple groups [101]. For example, a 
study of yeast cell cycle microarray data showed that only about 10% analyzed genes 
were mapped to a single cell cycle phase, while the rest were regulated in multiple 
phases [102]. Some attempts were done to alleviate the problem, for example in fuzzy 
k-mean clustering [103] that uses principal component analysis to identify 
overlapping groups of objects by allowing the objects to belong to more than one 
group. 
1.5.4. Advanced methods 
More advanced, pattern recognition algorithms in contrast to clustering methods 
try to recover a set of underlying patterns of expressions that combine differently for 
each gene to result in the observed gene expression profile. In this case, the 
expression profile of each gene can be interpreted as a mixture of different expression 
patterns that relate to different biological processes, therefore, allowing one gene to 
belong to multiple groups of co-expression. Mathematically, pattern recovery maps to 
a process of finding such matrices, the product of which equals the original 
microarray data matrix plus the noise. Examples of matrix factorization approaches 
are Singular Value Decomposition (SVD), Principal Component Analysis (PCA, 
special case of SVD), Non-negative Matrix Factorization (NMF), Independent 
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Component Analysis (ICA), and Bayesian Decomposition (BD) (these methods are 
reviewed in Chapter 2).  
1.6 Gene Annotations 
 
Microarray data analysis is a very demanding task involving multiple steps of 
data pre-processing, normalization, filtering, data mining, and interpretation of 
results. Many stages of the process can be enhanced by additional biological 
knowledge about the objects being analyzed, e.g. the gene linked to each probe, 
groups of co-expressed genes, or gene ontology (GO) information, which has recently 
become very popular [104-107] to aid validation of clusters or expression patterns 
recovered by data analysis.  Therefore, comprehensive and structured annotations for 
all probes on a microarray slide are very essential for the analysis. Currently, most 
microarray platforms provide annotation files for each chip they produce, however, 
these annotations are usually partial, outdated and unsuitable for high-throughput 
experiments. While it is possible to perform manual annotations for a limited number 
of probes using external annotation databases, such a non-automated process is very 
time consuming and requires deep knowledge of information sources to be able to 
combine collected information. 
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Figure 4. Example of annotations required at each step of microarray data analysis 
 
 
 
Figure 4 describes basic microarray data processing steps and types of 
annotation data that can be utilized at each of these steps. Generally, normalization 
does not require any biological knowledge about data points being normalized, but 
there are methods that use housekeeping or other constitutively expressed genes for 
normalization of data. Combining replicates can be another step prior to data mining 
and depending on the level of replicates it requires mappings of a probe to sequence 
accession number or gene symbol. Filtering is yet another pre-processing step that 
uses gene annotations of probes. Apart from removing entries that do not vary over 
experimental conditions or do not have specific expression profile determined by the 
design of the experiment, the process can also be aimed at filtering out probes that do 
not have any gene associated with them in order to focus analysis on true signals that 
are actually belong to known genes.  
Depending on data mining algorithm used for analysis of microarray data, gene 
annotations can be used to form training sets from genes of specific functional class 
for supervised algorithms, e.g. support vector machines (SVM) [108, 109] or neural 
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networks [110]. Another type of prior information for the analysis can be in a form of 
genes grouped by the biological process or by shared transcription factor. Such 
additional information added to the analysis can benefit the efficiency of an algorithm 
or improve statistical significance of final results. This prior knowledge can also be 
used for the algorithm validation when the method results are compared to already 
known information. 
Results interpretation step can use a very broad variety of annotation information 
about genes under study, including gene ontology information, pathways, 
transcription factors, chromosomal location, etc. Analysis of common features 
between genes from the same groups determined by data mining can help to link 
these features to observed expression behavior.  For example, abundance of genes 
related to apoptosis in a group can be linked to response of cancer patients to a 
treatment based on expression pattern common for these genes, whereas a common 
transcription factor for these genes can indicate activity of a certain upstream 
signalling pathway that lead to such response.  
Several systems have been proposed and implemented to provide integrated 
access to a number of various available genomic databanks. There are different types 
of such systems that differ in data management:  data warehousing, for example 
NCBI/Entrez [111], Swiss-Prot/TrEMBL [112], Ensembl [113],  Kyoto Encyclopedia 
of Genes and Genomes (KEGG) [114], Gene Ontology Consortium [115], which host 
and manage unique information. Information linking systems, e.g. the most popular 
SOURCE [116], GeneLynx [117], GeneCard [118], mediate access to different data 
sources through a Web interface to receive integrated annotations that can be linked 
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to original sources. However, most of these systems provide only one gene at a time 
annotations and are designed for human access, but not for computer-based querying. 
Thus, these systems are limited for use when thousands of diverse annotations are 
required, especially when results from one search should be used as an input for 
different data source. Therefore, large datasets require additional automated tools for 
gathering and composing the information of interest from available databases. 
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CHAPTER 2: PATTERN RECOGNITION METHODS OF MICROARRAY 
ANALYSIS  
2.1 Singular Value Decomposition and Principal Component Analysis 
The Singular Value Decomposition (SVD) and closely related Principal 
Component Analysis (PCA) method in application to gene expression data were first 
introduced by Alter et al. [119], where they analyzed the yeast cell cycle data set 
generated by Spellman et al. [120]. Later, these methods became the most popular 
matrix factorization algorithms and have been reported to be successfully applied to 
many other datasets, for example genetic profiling in leprosy [121], analysis of Down 
syndrome [122],  human fibroblast data [123],  breast tumor classifications [124], 
tissue specific gene expression pattern search [125],  to name a few. 
The basic concept behind the SVD is the following. Let D [n, m] denote a 
data matrix of n genes over m samples (conditions) with rank r as shown in Figure 5. 
In this case dij is the expression level of the ith gene in the jth sample. The elements of 
the ith row of D form the m-dimensional vector gi, which is referred to as the 
transcriptional response or expression profile of the ith gene. Alternatively, the 
elements of the jth column of D form the n-dimensional vector aj, which is referred to 
as the expression profile of the jth sample. Singular value decomposition of the matrix 
D produces two orthonormal bases, one defined by right singular vectors and the 
other by left singular vectors, as described by the equation:  
TUSVD =                                                                                                    (1)  
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where columns of U [n, m] are the left singular vectors (form an orthonormal basis 
for the sample expression profiles), S [m, m] is a diagonal matrix of ordered singular 
values, and the rows of VT [m, m] are the right singular vectors corresponding to 
ordered singular values that form an orthonormal basis for the gene transcriptional 
responses (Figure 5). Therefore, gene transcriptional response gi can be described as a 
linear combination of the right singular vectors also called eigengenes. Alternatively, 
sample expression profile aj can be presented as linear combination of the left 
singular vectors called eigenassays. In other words, eigenenes represent expression 
patterns found in the data and eigenassays define what genes contain corresponding 
pattern. 
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Figure 5. Singular Value Decomposition. Initial matrix D is decomposed into product of left singular matrix U, 
diagonal matrix of ordered singular values S, and right singular matrix VT 
 
 
 
In some cases it may be practical to reduce matrices dimensionality to p < m, 
then only the p largest singular values are calculated, while the rest of the matrix is 
discarded (Figure 6). This way, only p expression patterns will be found in the 
process. This approach is much quicker and more economical than SVD for m >> p 
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columns. The truncated SVD is not an exact decomposition of the original data 
matrix, however, the approximation may be sufficient for practical applications, 
especially to remove signals that represent the noise. 
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Figure 6. Truncated Singular Value Decomposition. It is possible to discard smaller singular values, keeping only 
first p singular values that keep most of the expression information.  
 
 
 
Principal component analysis is sometimes used as a synonym to SVD and is 
actually a special case of singular value decomposition, i.e. PCA uses SVD to project 
initial matrix into reduced space. PCA projects data into direction with the most data 
variance via linear transformation. A new coordinate system is selected in such a way 
that the greatest variance of the data is located on the first coordinate (called the first 
principal component), the second greatest variance on the second coordinate, and so 
on, while principal components are orthogonal to each other. Retaining of only p < m 
lower-order principal components as expression patterns allows matrix 
dimensionality reduction while keeping the strongest data variations.  
 One of the most valuable features of SVD and PCA is that it is possible to 
determine a number of expression patterns that explain the data by filtering out the 
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eigengenes (or high-rank principal components in case of PCA) that represent noise 
or experimental artifacts [119]. Using this property, PCA can be used to obtain true 
dimensionality of the data for methods that require to define number of clusters prior 
to analysis [126]. Also, SVD is capable to detect biologically meaningful patterns of 
expression, even when clustering methods fail due to weak signals in the data [127]. 
The major issue of PCA method is the restriction of orthogonality it imposes 
on underlying expression patterns. If the observed signals (PCs) are not orthogonal by 
nature, which is generally true for biological data, PCA does not produce biologically 
meaningful expression patterns. Another SVD/PCA shortcoming is that they do not 
take into account any error measures associated with the data points, although a  
recent modification made for PCA tries to solve the issue [128]. Absence of 
parameters to tweak and coefficients to adjust for the method can also be considered 
as an issue for the method, because some prior information about observed signals is 
available, an inability to incorporate this information into analysis is a significant 
drawback of the method. 
2.2 Independent Component Analysis 
Application of the Independent Component Analysis (ICA) approach to gene 
expression data was introduced by Liebermeister [129]. He compared ICA with PCA 
to show that introduction of non-orthogonal basis for dimensionality reduction is 
more biologically meaningful and takes into account high-order dependancies in the 
data. The original work [129] analyzed yeast cell-cycle data [120] and B-cell 
lymphoma data [130]. In more recent studies, ICA has also been applied to 
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classification of ovarian cancer [131], study of endometrial cancer [132] and 
diagnosis of human cancer types [133]. 
Like PCA, ICA performs data matrix decomposition by projecting initial data on 
a lower dimensionality space.  However, by removing all linear correlations, ICA 
allows a non-orthogonal basis for such decomposition, but it still requires statistical 
independence of components between each other. By stating that observed microarray 
signals are a result of a mixture of underlying biological processes in the cell, 
decomposition of matrix D can be expressed by the following equation: 
D = f(AP)                                                   (2.2.1) 
where matrix P includes statistically independent biological processes, and matrix A 
is a mixture matrix showing for each gene what biological processes contribute to the 
expression profile of the gene. In case of linear ICA, 
D = f(AP) = AP                                                                                       (2.2.2) 
In order to find matrix P, the linear ICA problem may me formulated as follows: 
P ~ Y = WD                                                                                            (2.2.3) 
where we need to find a matrix W (called the unmixing matrix), so that rows of 
matrix Y are as statistically independent as possible. In this case, Y will be a close 
approximation for P, up to permutation and scaling. 
 The process of finding the unmixing matrix can be performed by different 
algorithms, based on different metrics of statistical independence. For example, 
maximum likelihood estimation, a statistical approach for finding estimations of 
unknown parameters that result in the highest probability for observations [134], can 
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be applied. Another approach is to maximize negentropy (or equally minimize mutual 
information), given by the following equation: 
)()()( YHYHYJ gauss −= , where ∫−= dxxfxfxH ))(log()()(                    (2.2.4) 
Maximum non-gaussianity can also be used as a measure of independence by using 
the Kurtosis metric: 
224 }){(3}{)( YEYEYkurt −=                                                                          (2.2.5) 
where E(Y4) and E(Y2) are the 4th and 2nd moments of Y correspondingly. 
As has been mentioned earlier, ICA has the advantage over PCA of not 
imposing a requirement of recovered signal orthogonality, and is therefore more 
favorable for recovering mixed signals. ICA also has been shown [135] to outperform 
PCA, k-means clustering and the Plaid model on combined yeast cell-cycle [120], 
yeast stress [92], C. elegans [136], and human normal tissue data [137]. Overall, ICA 
is a fast, robust algorithm that is very well suited for microarray analysis. 
Although the statistical independence requirements of ICA is not as strict as 
orthogonality requirements of PCA, the assumptions about the independence of 
underlying processes may not be fully applicable in most microarray experiments. 
The method also does not take into account any error measures associated with 
microarray measurements and does not allow incorporation of prior knowledge into 
the analysis, leaving it prone to dimensionality problems from the large number of 
genes and minimal number of conditions generally under consideration. 
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2.3 Non-negative Matrix Factorization 
First introduced for facial feature recognition by Lee and Seung [138], non-
negative matrix factorization (NMF) was adopted for analysis of gene expression 
data. Various microarray analysis, including yeast mutants [139], classification of 
lung squamous cell carcinoma [140], analysis of leukemia [141] and toxicology  
datasets [142], have been analyzed using NMF since then. 
NMF operates on preprocessed data from a set of expression array 
experiments. The data comprises estimates of mRNA transcript levels (single 
channel) or ratios (two channel) represented as a single matrix D. Each row of D 
contains the mRNA estimates for each gene in all conditions (e.g., distinct tissues, 
experiments, timepoints), and each column corresponds to the estimates of mRNA 
levels for all genes in a single condition. For a dataset comprising I genes with 
expression measured in J conditions, the dimensionality of matrix D would be I × J. 
The goal of the NMF simulation is to find a small number of metagenes (the number 
of metagenes provides a dimensionality estimate), each defined as a positive linear 
combination of I genes. The mRNA level estimates across conditions for each gene 
can be approximated then as a positive linear combination of these metagenes. 
Mathematically, this can be expressed as an approximate factorization of matrix D 
into a pair of matrixes A and P as in equation 2.3.1: 
D = M + ε = A·P + ε                                                                                 (2.3.1) 
 The mock data, M, is the approximation of D, based on our estimates of A and P. 
The matrix ε provides for the error in the measurements in D. For K metagenes (i.e., 
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K dimensions), matrix A is of size I × K with each of the K columns defining a 
metagene. The value of element Aik indicates how strongly gene i is associated with 
metagene k. Matrix P is then of size K × J, with each row representing the relative 
mRNA levels of a metagene across the conditions. The value of element Pkj given the 
strength of metagene k in condition j.  
 For NMF simulation, random matrices A and P are initialized according to 
some scheme. For instance, they could be populated from a uniform distribution U 
[0,1]. The two matrices are then iteratively updated using the following rules: 
∑
∑←
i ii
i ii
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∑= k kjikij PAM                                                                    (2.3.4) 
which guarantees reaching a local maximum in Likelihood and minimizes 
 ∑ −=−
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ijij MDMD
22 )(                                                                             (2.3.4) 
In comparison to other factorization methods, NMF is capable of finding 
smaller, more localized patterns as well as global patterns [139], since it is doesn’t 
require special properties of recovered metagenes. The only assumption is a non-
negativity of the underlying signals that perfectly reasonable for additive nature of 
gene regulation. However, absence of such constraints has a tendency for recovering 
of signal-invariant metagenes that carry no or little information. This problem was 
addressed by Carmona-Saez et al. who developed modification to the method, non-
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smooth NMF (nsNMF) to produce sparse representation of the metagenes and 
encoding vectors by making use of non-smoothness constraints [143]. Although very 
robust, NMF do not account for uncertainty information of the data, providing an 
issue of overfitting the data, just as PCA or ICA. Recent modification of the method, 
least-squared NMF (LS-NMF), introduced new updating rules for matrices 
recalculation by incorporating error measurements and replacing criteria of distance 
minimization with minimization of chi-square error [144] to take advantage of 
uncertainty information. 
2.4 Bayesian Decomposition 
The Bayesian Decomposition (BD) algorithm initially was applied to spectral 
imaging [145] and then was adapted to analysis of gene expression data [45]. It was 
successfully applied recently for expression pattern recognition in yeast deletion 
mutant gene expression data [146], yeast cell-cycle data [45], mouse tissue specific 
expression data [147], lung adenocarcinoma microarray data [148], and Plasmodium 
falciparum life cycle expression data [149]. 
The basic principal behind the decomposition performed by BD is to recover an 
amplitude matrix (A) and a pattern matrix (P), the product of which yields a model of 
the data matrix (M) that reproduces the data matrix (D) within the noise level (Eqn. 
2.3.1), as shown in Figure 7. The initial matrix D represents measurements with 
errors for genes (rows) across different conditions or samples (columns). The 
recovered matrix P contains patterns of expression (rows) within the data and matrix 
A indicates the strength of the assignment of a gene to a pattern, thereby providing a 
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key feature to reflect the biological fact that one gene can be involved in multiple 
processes and have multiple patterns of expression. 
 
 
 
Figure 7. Decomposition performed by BD. Model matrix M is created by multiplication of matrices A and P 
recovered during the analysis to compare with initial the data matrix D [45]. 
 
 
 
The algorithm creates amplitude and pattern matrices using a Markov Chain 
Monte Carlo (MCMC) process based on Bayesian statistics [150]. Bayes’ equation is 
used to calculate conditional probability at each point of the Markov Chain, when 
changes in matrices A and P are created. That is, the probability of created matrices A 
and P to be a solution for the problem given the data D can be described by 
 
p(A,P|D) ~ p(D|A,P) p(A,P)                                                                     (2.4.2) 
 
where p(A,P|D) is the probability of the current model (posterior), p(D|A,P) is the 
likelihood, and p(A,P) is the prior probability of the created matrices A and P to be a 
solution independent of the data D. Each step of the MCMC process tests random 
changes made to matrices A and P according to the prior by determining the changes 
in the likelihood. Simulated annealing [151, 152] is used before sampling starts to 
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minimize the possibility of being trapped in a local maximum in the posterior 
distribution. That is done by modifying (2.4.2) to 
 
 p(A,P|D) = p(D|A,P)T p(A,P)                                                                   (2.4.3) 
 
where T is changed from 0 to 1, gradually increasing the influence of data on the 
posterior. After sampling begins, the MCMC process iterates for a given number of 
steps and returns the mean and standard deviation for each element of matrices A and 
P calculated from collected samples.  
The process of MCMC with application of Bayes’ formula can be 
implemented by creating an atomic domain with prior distributions and mapping to a 
domain of the matrices A and P. This provides an ability to encode prior biological 
knowledge into the model. In the original work [45] prior knowledge encoded was 
the positivity of gene expression (i.e. the ratio of the relative amounts of mRNA 
between experiment and control is a positive value) and abundance of low gene 
expression signals compared to higher ones. The prior is composed by using atomic 
domain abstraction. The atomic domain is a set of atoms that have an amplitude (or 
value) and a position on an infinitely divisible line (actually 2^32 points). Changes 
that could be applied to the atomic domain include creating an atom of random 
amplitude (exponential, (1/q)e^(-z/q) with q being mean flux) and putting it to a 
random position (uniform); deleting an existing atom or moving an existing atom 
from one position to another. Thus, probability space formed by these atoms 
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represents positive additive distribution that also reflects prior information about 
microarray signal, giving more probability to atoms with lower amplitudes. 
 
 
 
Figure 8. Creation of the prior by mapping atomic domains into the model. Mapping is done for each atom from 
atomic domain by convolution functions (fs), defined on atoms positions and amplitudes. Convolution functions 
shown simply map an atom to one element of a matrix, i.e. atoms denoted by thick lines would be mapped to the 
appropriate elements of matrix denoted by thick dot [45]. 
 
 
 
Atoms from the atomic domain are mapped to the model domain (matrices A 
and P) by using a convolution functions (Figure 8). A convolution function maps the 
amplitude of each atom from the atomic domain into the values of one or more 
elements in A or P. This mapping can be arbitrarily general. For example, a very 
simple convolution function is one that maps the amplitude of the atoms into a value 
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for one element of the target matrix [45] (Figure 9). Another convolution function 
may map one atom to a set of elements in matrix A that correspond to genes known 
to be co-expressed and therefore provide a mechanism for encoding additional prior 
knowledge into analysis. 
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Figure 9. Mapping of an atom by a simple convolution function. Atomic domain is divided on a number of bins 
equal to number of matrix elements, with each bin correspond to the specific matrix element. Thus, an atom’s 
amplitude is mapped to a matrix element that is determined by position of the atom. Atoms, 1 and 2 are mapped to 
the same element, while atoms 3 and 4 are mapped to different elements. 
 
 
 
 
2.5 Summary of reviewed methods 
All the reviewed advanced methods based on the model of matrix factorization 
allow assigning one gene to multiple groups of co-expression. In a process of matrix 
 37
factorization, it is possible to map recovered signals to expression patterns, which 
when mixed according to another matrix represent observed expression profiles for 
all genes from the initial data matrix. This way, PCA, ICA, NMF and BD are more 
favorable compared to clustering methods for analysis of microarray data, where 
biology dictates that genes will be regulated to function in more than one biological 
process.  
 It should be noted that assumptions for recovering of underlying signal can 
limit the applicability of the methods, e.g. orthogonality assumption of PCA or 
independance requirement of ICA may stop the methods to produce biologically 
meaningful patterns. While BD encodes information for expression patterns in a form 
of a prior, favoring patterns with a minimal structure, NMF does not have any such 
restriction except for non-negativity [143]. Absence of assumptions about underlying 
expression signals can also be a disadvatage when dealing with high noise in data, 
when outliers or missing points may lead the model to overfit the data.  
 Data overfitting is also inevitable when no noise model is introduced in the 
analysis. The original PCA, ICA and NMF methods do not have tools to handle 
variance measurements on microarray data, when modifications of PCA and NMF 
that target the issue were shown to improve performance of these methods. 
 The ability to include additional prior knowledge in the model is yet another 
desired property of a pattern recognition method for microarray analysis. This helps 
to address the issue of low the signal-to-noise ratio by including independant 
information in the model, allowing improving of the statistical power of results. 
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Bayesian Decomposition has an advantage over other methods, since it has 
mechanisms for such prior biological information inclusion in the form of the prior. 
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CHAPTER 3: ENHANCEMENTS TO BAYESIAN DECOMPOSITION  
3.1 Modification of Bayesian Decomposition with Coregulation 
Bayesian Decomposition uses a Markov Chain Monte Carlo process to create 
amplitude (A) and pattern (P) matrices that when multiplied together result in a model 
of the original data matrix (D) (Figure 7, section 2.4). While matrix D contains 
observed expression profiles, matrix P represents a suggested set of expression 
patterns (each row corresponds to a pattern) that relate to underlying biological 
processes, and matrix A indicates combination of which of these patterns yield the 
observed expression profile for each gene. Thus, the amplitude matrix A assigns each 
gene to patterns with varying strength, allowing one gene to belong to more than one 
pattern. A column of the amplitude matrix A can be interpreted as a group of genes 
that contain corresponding expression patterns from the pattern matrix P, i.e. as a 
group of co-expressed genes. Prior information about such gene co-expression can be 
used in the process of creating the amplitude matrix A, helping the algorithm to group 
together genes that have a high probability of being co-expressed. 
As described in section 2.4, prior information can be encoded into the 
Bayesian Decomposition algorithm in the form of probability distributions for the 
amplitude and position of an atom or using a convolution function that maps atoms 
onto the matrix model (Figure 8). In order to encode the co-expression information 
we created a convolution function that maps the atom into a set of A matrix elements 
corresponding to the genes that are known to be coregulated (Figure 10). The process 
of defining target matrix elements is similar to the one shown in Figure 9, except each 
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bin is defined by a unique pair (co-expression group k, pattern p) and corresponds to 
multiple matrix elements. Thus, the position of each atom from the atomic domain 
falls into a bin (k, p), which indicates the convolution function for co-expression 
group k and pattern p, i.e. column p in matrix A. The amplitude of the atom is 
mapped into the defined elements according to normalized weights for each gene. In 
order to reduce the negative consequences of a poor or incomplete prior in the model, 
the atomic domain is split onto two parts. For the first part a convolution function that 
maps an atom to a set of elements defined by coregulation information is used, and 
for the second part each atom is mapped to a single element of the matrix A.  
Normalization for the prior information is an issue that arises because of 
genes having different levels of expression and being involved in different sets of 
processes. This can be illustrated by Figure 11, where possible expression profiles of 
three genes known to be regulated in phase G1 are shown. The expression pattern that 
corresponds to only phase G1 is plotted as a dot line, and it is apparent that amplitude 
matrix values for these genes should be proportional to their expression levels in G1 
for a decomposition to be correct. Therefore, a convolution function that uses co-
expression information should spread an atom between elements of matrix A 
proportionally to expression levels of corresponding genes within that coregulation 
group. 
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Figure 10. Splitting the atomic domain. The atomic domain is split onto two parts. The position of an atom (to the 
left or to the right of the split) in the atomic domain defines what convolution function will be used for its 
mapping. The convolution function that uses prior co-expression information (f1) spreads the amplitude of the 
atom into elements in matrix A defined by the position of the atom (black dots in matrix A defined by position that 
resulted in using group K and pattern 1). The simple convolution function (f2) is used to map an atom directly to 
appropriate element defined by the atom position (gray dot in matrix A). 
 
 
 
0
5
10
15
20
25
30
35
G1 S  
Figure 11. Expression profiles of genes coregulated in phase G1. Green, red and blue lines represent possible 
expression profiles of three genes. Dotted line shows expression pattern that corresponds to phase G1. 
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Given a number of coregulation groups T, we address the normalization issue 
by generating T overlapping subsets, with a subset t (t = 1..T) consisting only of data 
for genes from one group, and applying original Bayesian Decomposition to each of 
these subsets (Figure 12). The number of patterns posited into analysis for each 
subset is equal to M +1, where M is the total number of groups that contain any gene 
from the subset. This provides for a pattern for each coregulation set plus a pattern for 
routine metabolic function, which BD typically isolates in a separate pattern. The 
recovered amplitude matrices are used to determine the strongest pattern that explains 
the data subset: first, we normalize each row of matrix A (Ai) to the sum of 1: 
∑
=
=
Pj
ij
i
i A
AA
,1
,                                                                                  (3.1.1) 
then, the strongest pattern corresponds to the column that gives the smallest variation 
coefficient (standard deviation over mean value) of normalized amplitudes. The 
strongest pattern pstrongest is used to assign weights to each gene k of the group by 
calculating a dot product between the pattern and expression profile of the gene: 
∑=
j
strongest
jkjk pdw                                                                                (3.1.2) 
The convolution function spreads the amplitude of an atom proportionally to the 
received weights for each gene from the co-expression group that corresponds to the 
atom. 
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Figure 12. Calculating normalization weights. The figure shows example of the calculation process for three co-
expression groups A, B and C. New subsets DA, DB and DC are generated and BD is used for decomposition. After 
determining main pattern for each subset using recovered amplitude matrices AA, AB and AC, dot products of main 
pattern and a subset are calculated to receives weight matrices WA, WB and WC for each group of genes. 
 
 
 
3.2 Testing Enhancements to Bayesian Decomposition 
3.2.1 Introduction 
We performed testing of the modified Bayesian Decomposition on three separate 
sets of data. First, we created a data set that simulates expression measurements of 
cell-cycle regulated genes. The simulation allowed us to control all the parameters, 
including underlying expression patterns, gene distribution between these patterns, 
and noise levels of modeled measurements. Next, we used a well studied yeast cell-
cycle data set [90] (second data set) and yeast mutant (also known as Rosetta 
Compendium) data set [153] (third data set) to test enhancements done to BD on real 
microarray data. A wide knowledge base available for S.cerevisiae made it possible 
to acquire highly conservative regulation data about the genes under study, to 
compose prior information for modified BD, and to create a gold standard for 
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comparison of original and modified BD and other methods, such as hierarchical and 
k-means clustering. 
In order to compare two algorithms between each other we used receiver 
operator characteristic (ROC) analysis [154] performed for groups of co-expressed 
genes received as a result of BD. Basically, a point of an ROC curve can be 
calculated by counting the number of true positive (TP), true negative (TN), false 
positive (FP) and false negative (FN) assignments of all genes to groups and 
calculating the specificity and sensitivity values: 
FPTN
TNySpecificit
FNTP
TPySensitivit
+=
+=                                                                             (3.2.1) 
Such groups used for calculating true and false positives and negatives are generally 
called a gold standard and have to be very reliable. To get other points of the ROC 
curve, analyzed algorithm should provide distinct grouping of genes by varying 
available parameters or thresholds. Then ROC curve is plotted as points of (1-
specificity, sensitivity) and area under the curve (AUC) can be used as an efficacy 
measurement of the tested algorithm (Figure 13). 
ROC analysis was performed for BD by increasing the stringency of assignment 
of a gene to a pattern. Essentially, each gene has a mean value of its strength within a 
pattern and an uncertainty on that assignment from amplitude matrix A based on the 
MCMC sampling.  By increasing the number of standard deviations away from zero 
required to assign a gene to a group, multiple estimates of the assignment of the genes 
to the patterns were made, allowing the ROC curve to be constructed. 
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Figure 13. Examples of ROC curves. Blue, green and red lines represent three algorithms. Plotted as 1-specificity 
against sensitivity, blue curve correspond to the best of the three methods, green is less accurate than blue, and red 
is an example of algorithm that generates results randomly. 
 
 
 
3.2.2 Testing on simulated data 
First, validation of our modifications to Bayesian Decomposition was 
performed using a simulated gene expression data set modeling yeast cell-cycle. We 
created amplitude (A) and pattern (P) matrices (Figure 14) and multiplied them 
together to generate an ‘ideal’ data matrix. The pattern matrix included 5 overlapping 
patterns imitating expression profiles of 4 cell-cycle phases (G1, S, G2, M) and a 
metabolic oscillator taken through 2 full cycles (48 sample points) [45, 90]. 
Amplitude for cell-cycle imitating patterns had the value of 3 and metabolic oscillator 
alternated expressions of 0.15 and 0.1. The amplitude matrix was created to simulate 
expression profiles for genes whose expression is regulated at multiple phases of the 
cell cycle: 288 genes were randomly assigned with a combination of patterns, so that 
126 genes were regulated in phase G1, 122 genes in phase S, 116 genes in phase G2, 
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115 genes in phase M and 64 genes had an expression pattern of a metabolic 
oscillator. Overall, 72 genes contained only one, 181 genes contained two, 31 
contained three and 4 contained four expression patterns.  
 
 
 
Figure 14. Simulated A and P matrices. Matrix A consists of 288 genes with expression linked to 5 patterns. Black 
stripes show if the gene shows expression related to the pattern. Matrix P consists of 5 patterns, simulating 4 cell-
cycle phases and a metabolic oscillator.  
 
 
 
To reflect noisy signals the data matrix was distorted, including different 
levels of additive and multiplicative noise as expected for microarrays [155, 156], i.e. 
)(),0( ),0( PAeND bNa ⋅⋅+= σσ                                                            (3.1.4) 
where A and P are simulated amplitude and pattern matrices, and σa and σb are 
additive and multiplicative levels of noise respectively. Data matrices with 154 
different noise levels were created, varying additive noise levels from 0 to 6.5 with 
step 0.5 and multiplicative noise levels from 0 to 3 with step 0.3 with the data matrix 
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without noise having maximum amplitude 3.15 and mean amplitude 0.65. While peak 
expression levels in the ideal matrix D had a value of 3.15, variation of the noise 
levels provided noise coverage (noise levels of more than 100% of signal σa=6.5 and 
σb=3) that is far beyond error levels of real microarray data (10-30% of signal). For 
each noise level 4 replicates of matrix D were created representing an experiment 
with four replicates and mean and standard deviation of mean were used for the 
simulation. 
The 154 data matrices with different levels of noise were processed with 
original and modified versions of BD. Each data matrix was analyzed using four 
different random seeds (different starting points for Markov Chain Monte Carlo) 
positing 5 patterns in the model, which corresponds to: 
48..1,288..1,~
5
=== ∑ jiPAMD kjikijij                                                  (3.1.5) 
Prior knowledge of gene co-expression provided to the modified BD algorithm was 
composed by taking information from the simulated matrix A with different coverage 
– 1 (all information – 5 groups with 126, 122, 116, 115 and 64 genes), 0.9 (5 groups 
with 113, 113, 103, 104 and 50 genes), 0.75 (5 groups with 100, 92, 87, 80 and 54 
genes), 0.5 (5 groups with 64, 62, 55, 59 and 39 genes) and 0.25 (5 groups with 30, 
31, 23, 29 and 16 genes).  
Results were compared for each level of noise and for each level of prior 
information included between the original and modified BD. The χ2 fit between 
simulated and calculated amplitude matrices and the value of the area under the ROC 
curve for grouping the genes determined from the amplitude matrix were used for the 
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comparison. Figure 15 shows results in a form of heat maps where orange-red blocks 
indicate an advantage of using the modified version of BD at the given noise level 
and blue blocks indicate a disadvantage (green indicates no significant difference). 
The results for simulated data demonstrate that increasing the amount of available 
prior information about gene coregulation in the analysis allows the modified BD 
more accurately find patterns in noisy data. Although there are rare points of noise 
levels where original BD performs better, typical modern arrays have noise levels in 
the lower left quadrants and including prior information always showed better results 
at these levels. 
 
 
A 
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Figure 15. Comparison of original and modified Bayesian Decomposition based on simulated data.  
Red-yellow bars identify levels of noise where modified BD showed better results, and magenta-blue bars 
identyfy where original. Green bars show insignificant difference. A. Figure shows log2 ratios between chi-
squared distances for original and modified BD with different amount of prior information included (25%, 50%, 
90%, and 100%). Chi-squared is calculated between ideal and recovered amplitude matrices. B. Figure shows log2 
ratios of areas under ROC curve for original and modified BD with different amount of prior information included 
(25%, 50%, 90%, and 100%). Areas under ROC  are calculated using information of ideal amplitude matrix as 
gold standard for recovery results. 
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We also analysed number of atoms required for the algorithm to fit the data at 
different noise levels. At each noise level, average number of atoms used by BD for 
the amplitude (N(A)) and pattern (N(P)) matrices were received from MCMC 
sampling for both original BD and modified BD when all prior information was used. 
Figure 16 presents histograms that show distribution of differences between number 
of amplitude matrix atoms (A atoms, on the left) and between number of pattern 
matrix atoms (P atoms, on the right) used by original and modified BD to fit each of 
154 data matrices. While histogram for pattern matrix show no difference of P atoms 
used by both versions of BD (average difference value of 0), average number of A 
atoms used by modified BD (643) is less than average number of A atoms used by 
original BD (753)  yeilding the average difference value of 110. These results 
indicate that the enhancements made to the BD algorithm work as intended, requiring 
to create less amount of atoms, in other words less amount of information, to find the 
amplitude matrix. 
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Figure 16. Histograms of atoms number differences between original and modified BD. Histograms are built 
based on 154 values, one for each level of noise. Atoms number difference for atomic domain that corresponds to 
the amplitude matrix is on the left. Atoms number difference for atomic domain that corresponds to the pattern 
matrix is on the right. 
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3.2.3 Testing on biological data: yeast cell-cycle dataset 
Validation of the modified Bayesian Decomposition on simulated data 
showed that incorporation of prior coregulation information into the analysis can 
significantly increase the ability of the algorithm to recover the correct groups of co-
expressed genes. While simulated data provides unique control over all testing 
conditions, including most importantly knowledge of the correct results, a biological 
example needs to be analyzed to confirm the power of the algorithm. The problem of 
the lack of a gold standard measurement can be partially overcome by choosing a 
biologically well-characterized system. Budding yeast (S.cerevisiae) is a well-studied 
model organism with standard data sets analyzed by various algorithms, providing an 
additional opportunity to check the efficacy of BD against other methods. 
 The cdc28 temperature-sensitive mutant yeast cell cycle data [90, 120] 
comprises measurements of gene expression levels over 160 minutes covering two 
complete cell cycles. Patterns of expression found within the data can be mapped to 
cell-cycle phases and distribution of genes among these patterns makes it possible to 
group genes into co-expression sets. The yeast cell cycle data set was widely used to 
test different algorithms including singular value decomposition [119], independent 
component analysis [129], cooperative vector quantizer [157] and shrinkage-based 
cluster analysis [94]. The latter has a receiver operating characteristic (ROC) curve 
[158] built on the results of clustering analysis that is compared with ROC curve built 
on the results from BD. 
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Yeast cell cycle data comprises 788 cell-cycle regulated genes with 
expression measured across 17 time points. Missing points were replaced with value 
of 1.0 with uncertainty of 9079 - the maximum value of the dataset, so BD wouldn't 
be constraint by such points. The prior knowledge about genes coregulation were 
taken from literature by searching evidences of genes regulation by one transcription 
factor that wasn't based on microarray data. It resulted in 11 groups contained from 5 
to 17 genes in each, 67 genes in total and 18 from them belong to more that one 
group (see Table 1). 
 
 
Table 1. Coregulation data [94] used for analysis of yeast cell-cycle data 
Group Regulator Target genes 
1 Mot3 Hxt4, Suc2, Cyc1, Sst2, Hxt2 
2 Ndt80 Clb1, Clb6, Clb4, Sps4, Clb5 
3 Ste12 Tec1, Fus1, Far1, Cln1, Mfa2 
4 Swi5 Pcl2, Pcl9, Ash1, Sic1, Egt2 
5 Cbf1 Met10, Met28, Met3, Met17, Met25, Met16 
6 Fkh1 Swi5, Alk1, YIL158W, Bud4, YPL141C, Clb2 
7 Fkh2 Swi5, YIL158W, Bud4, Ace2, YLR190W, YPL141C, Kip2, Clb2 
8 Swi6 Ho, Rnr1, Swi4, Cdc6, Cln1, Cdc21, Cln2, Clb5 
9 Mcm1 Cln3, Swi5, Mfa1, Swi4, Ste2, Far1, Cdc6, Ace2, Cdc46, Clb2 
10 Swi4 Pcl2, Ho, Mnn1, Och1, Cis3, Cwp1, Gls1, Cln1, Pcl1, Srl1, Svs1, Cln2, Kre6 
11 Rlm1 Pst1, Sed1, Crh1, Mpk1, Sec28, YIL117C, Cis3, Pir2, Cwp1, Pir3, Pir1, YLR194C, Fks1, Dfg5, YMR295C, YNL058C, Ygp1 
 
 
 
Number of patterns posited into the analysis was from 4 to 7 and reflected the 
nature of the data to contain just cell-cycle regulated genes. We analyzed the data set 
with both the original and modified BD and results were compared to determine the 
effect of prior knowledge. We used two different gold standards for the ROC 
analysis. First gold standard consisted of prior knowledge groups from Table 1 used 
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by modified BD for the analysis. Second gold standard was based on the known 
molecular biology of gene coregulation independent of microarray studies and 
comprised 9 groups with 43 genes total used by Cherepinsky et al. [94] to build the 
ROC curve for hierarchical clustering algorithm available to compare with both BD 
methods. 
In Figure 17 we present results of the application of modified BD to the cell 
cycle data using ROC analysis. We compared the results using the original BD 
(circles), modified BD (squares), and shrinkage-based hierarchical clustering 
(triangles) performed previously [94]. On the left, the ROC curve is build using gold 
standard from Table 1 and shows that prior coregulation information was successfully 
used by modified BD to provide the results of better accuracy than original BD. On 
the right, Cherepinsky et al. groups were used as gold standard and modified BD 
obtains an area under the curve of 0.82, compared with 0.83 for original BD and 0.56 
for the best hierarchical clustering method. The lack of improvement from use of 
coregulation information reflects the limited nature of such data for these genes at the 
present time.  In this case, we have prior data on only 67 of 788 genes, which was not 
adequate to improve inference over BD.  However, we include the results to show the 
value of both original and modified BD, due to assignment of genes to multiple 
groups. 
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Figure 17. Results of yeast cell-cycle analysis. Left figure shows ROC curves for original and modified BD based 
on golden standard from Table 1. Right figure shows comparison of ROC curves for BD with hierarchical 
clustering based on groups from Cherepinsky et al. [94]. 
 
 
 
3.2.4 Testing on biological data: Rosetta compendium dataset 
 The Rosetta Compendium data set [153] contains microarray profiling of 300 
diverse mutants and chemical treatments in S.cerevisiae and of 63 wild type control 
samples grown in rich media. Because S.cerevisiae has several MAPK signaling 
processes, expression patterns recovered from this data may be mapped to signaling 
pathways. Specific mutants with a knocked-out gene in a key pathway component 
offer the opportunity to validate the transcriptional patterns related to pathways. 
The data set was analyzed with both the original and modified BD algorithms 
and an ROC analysis was performed to compare efficacy of both algorithm versions. 
The gold standard set used in the yeast cell cycle data set could not be used here as 
the specific genes show little variation in the Rosetta data set, which is not 
unexpected as all cultures were actively growing and unsynchronized, and therefore 
they showed active but average levels of expression of the cell cycle genes. 
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Coregulation information included as prior knowledge in the modified version 
of BD was obtained similarly to yeast cell-cycle data from biological literature based 
on reported transcription factors and their target genes, determined with methods 
other than microarrays (Table 2). The same data was used as the gold standard for the 
ROC analysis. We ran with both the original and modified BD positing from 10 to 20 
patterns into the analysis.  
 
 
Table 2. Coregulation data used for analysis of Rosetta compendium data 
Group Regulator Target genes 
1 Zap1 Adh4, Oye3, Zrc1, Zrt1, Zrt2 
2 Ndt80 Clb1, Clb6, Dit1, Sps1, Sps4 
3 Mcm1 Clb2, Far1, Mfa1, Mfa2, Ste2, Ste6 
4 Gcn4 Atr1, His3, His4, His7, Ilv2, Rad16 
5 Dal80 Dal3, Gap1, Gdh1, Put1, Put4, Uga4 
6 Rtg1 Aco1, Cit2, Idh1, Idh2, Pdr3, Pdr5, Pox1 
7 Pdr1 Pdr10, Pdr15, Pdr3, Pdr5, Ste6, YAL061W, YLR346C 
8 Met4 Ecm17, Met14, Met16, Met17, Met17, Met3, Met6 
9 Ume6 Dit1, Ime1, Ime2, Ino1, Opi3, Sip4, Spo13, Sps2 
10 Ste12 Far1, Fus1, Mfa1, Mfa2, Muc1, Pgu1, Ste2, Tec1 
11 Mot3 Dan1, Hxt2, Hxt4, Leu2, Sst2, Suc2, Tir1, Tir4 
12 Gln3 Dal3, Gap1, Gdh1, Gdh2, Put1, Put4, Uga4, Ura3 
13 Cbf1 Gal2, Met10, Met14, Met16, Met17, Met17, Met3, Sam2 
14 Mig1 Dsf1, Emi2, Hxk1, Hxt13, Hxt2, Hxt4, Reg2, Suc2, YFL054C, YLR042C 
15 Rlm1 Crh1, Ctt1, Cwp1, Fit2, Pir3, Prm5, Pst1, Sed1, Slt2, Sps100, Ygp1, YLR194C 
16 Msn4 Adh2, Ahp1, Glk1, Gph1, Gre2, Gsy1, Hsp104, Hsp26, Hsp30, Hxk1, Ime1, Msc1, Pgm2, Rnr3, Rtn2, Sol4, Spi1, Suc2, YNL194C 
17 Msn2 Ahp1, Ctt1, Glk1, Gph1, Gre2, Gsy1, Hsp104, Hsp26, Hsp30, Hxk1, Ime1, Msc1, Pgm2, Rnr3, Rtn2, Sol4, Spi1, Suc2, YNL194C 
 
 
 
Figure 18 demonstrates results of the analysis of Rosetta compendium data. 
Results from using modified BD (squares) were compared to K-means clustering 
(triangles) and the original BD analysis (circles) of the same data. Here, both the 
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coregulation information and the gold standard gene lists were the same, so that the 
results demonstrate that the algorithm correctly used information about transcription 
factor regulation and that such coregulation is reflected in the data.  All techniques 
performed equally well at high specificity, however as sensitivity increased, modified 
BD was superior in terms of reduced false positives due to the inclusion of prior 
information on expected coregulation. 
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Figure 18. Results of Rosetta compendium data analysis. Figure shows comparison of ROC curves for original 
and modified BD along with k-means clustering. 
 
 
 
3.3 Summary 
 Testing of enhancements done to Bayesian Decomposition on simulated data 
showed the advantage of using coregulation information, as it increases as levels of 
prior information increase. The observed behavior indicated improvement of 
statistical inference compared to the original BD algorithm. Reduction of A atoms 
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required for the algorithm to find correct solutions also indicated the success of 
development of modified Bayesian Decompostion. BD enforces an additional 
constraint on the prior and therefore there is a preference for minimization of 
structure, which takes the form of a tendency to use fewer atoms.  This Occam's razor 
argument leads to relatively sparse matrices.  
 Testing performed with real biological data revealed that even with the small 
amount of prior coregulation information, modified BD performs equally well or 
better than original BD. Although yeast cell-cycle dataset analysis showed no 
difference in efficacy between both versions of the algorithm when compared to 
golden standard that was not included as prior knowledge, results check based on the 
data included as prior coregulation information demonstrated advantage of using such 
information in order to improve statistical power. Rosetta compendium dataset results 
interpretation showed that both algorithms performed equally well at high specificity, 
while as sensitivity increased, modified BD was superior in terms of reduced false 
positives due to the inclusion of prior information on expected coregulation. 
This work demonstrated the value of inclusion of prior knowledge of 
transcriptional regulation in the analysis of microarray data and also the present limits 
on that knowledge. While the simulations showed a clear advantage in using this 
knowledge, the analysis of yeast data indicates the present lack of coregulation 
information available.  Nevertheless, the superiority of the modified BD approach is 
clear. Our knowledge of transcriptional regulation is rapidly increasing, and we 
expect improved statistical power with modified BD over the next few years. This 
 57
power will be critical to improved inference of biological process activity, especially 
with heterogeneous and limited samples typical in clinical settings. 
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CHAPTER 4: AUTOMATED SEQUENCE ANNOTATION PIPELINE  
4.1 Automated Sequence Annotation Pipeline concept 
In order to maximize discovery, a vast amount of biological information about 
genes are available to guide microarray data mining, starting from identifying probes 
on microarray slides and ending with interpretation of results received by a data 
processing algorithm (Figure 4, section 1.6). While general annotations frequently 
can be done through various systems that provide web access to databases of interest, 
specific requirements usually demand using output of one query as an input for 
another, and often a researcher wishes to use different internet sources for the task. 
The annotation process therefore becomes time consuming, and the user is expected 
to have an expertise in different queried systems. The manual processing is also 
complicated if annotation is performed for a list of entries and the target sources do 
not support batch queries, especially when the list needs regular updating due to 
constantly changing information from annotation sources. Finally, an investigator 
needs to post-process received annotation information to organize it in a format 
required for data mining or result interpretation software. 
In order to overcome most of the issues of manual annotation, we created the 
Automated Sequence Annotation Pipeline (ASAP) system [159] to automate 
acquiring of annotations. We use it as a part of a data mining process that supplies 
microarray data analysis at each step. The ASAP system serves as a mediator 
between the user and various data sources, using results from one query as input 
parameters for another to receive annotations for the user’s data (Figure 19). Data 
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sources available for ASAP to query can be of various types and located in different 
sites. For example, remote dababases with web access by http or ftp protocols can be 
a valuable source of annotation information. Also, local programs can be used by 
ASAP to run them and receive results of calculations, which can form part of the 
information required by the user. Finally, local database can be used to store 
information once acquired from other sources. It allows caching results to provide 
quicker and more reliable access to them without querying remote databases that can 
be slow and even unavailable at the moment of request. 
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system
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Figure 19. Automated Sequence Annotation Pipeline system. User passes input data and ASAP system performs a 
series of queries, using user’s input and results from other queries. Output is formed from the results of queries 
and passed back to user.  
 
 
 
ASAP performs annotation of user input data by executing pre-designed 
annotation plans that represent a script of directives, which include specifics of what 
data sources to query, what format the target source accepts query input, and how to 
extract information (results) from the received data. Also, annotation plans contain 
descriptions of formats available for user output. Thus, ASAP represents an 
environment where annotation plans are stored and run.  In addition, the system 
generates reports for the administrator about possible changes in query input formats 
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or availability of remote sources. This is especially important for the system, since it 
assumes fixed standards that can change without notice. 
Another feature in the system is the allowance for multiple users that can work 
on different operating systems.  In addition, there is also a need to have up-to-date 
information for querying. Due to these demands, ASAP was designed as a web-
application with a central linked local database, and it requires a researcher only to 
have an internet browser to access the pipeline. Two distinct web interfaces were 
created to separate functions available for regular users and administrators of the 
system. The user part provides an interface to basic functions of ASAP, such as 
submitting a job by querying an annotation plan of interest with parameters, checking 
status of the jobs and downloading results of annotations. The administrator part 
consists of various maintenance functions, including user management, basic system 
parameters configuration, detailed job information handling and, most importantly, 
new annotation plan installation and editing functions. A complete list of scenarios 
(also called use cases) available for user and administrator roles is shown in Figure 
20, and descriptions of these use cases are provided in Table 3. 
4.2 Automated Sequence Annotation Pipeline implementation 
ASAP is implemented as a client-server web application using the Perl language 
as shown in Figure 21. Users access the system with the web interface through web 
browsers that support cascade style sheets, e.g. Internet Explorer, Safari, Opera or 
Firefox. The system can be installed on Linux or Windows platforms under the 
Apache server that supports execution of Perl scripts. On the back end ASAP uses a 
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relational database (mySQL) to store information about system users, performed 
tasks, status of jobs, and other user and administrator related information. A local 
database is also used to store annotation information acquired earlier. Various 
supported protocols of access allow ASAP core functions to access remote and local 
data sources both local and remote. 
 
 
 
Figure 20. Use case diagram for ASAP system. Use cases available for administrators (MAIN ADMIN, ADMIN) 
and regular users (USER, GUEST) are shown and descriptions are provided in table. 
 
 
 
 
 
 62
Table 3. Description of ASAP use cases 
Use Case Description 
Register This use case allows GUEST to register in the system by setting username, password and 
e-mail. 
Login If GUEST is registered in the system the use case allows for GUEST to log in into the 
system and become a USER. 
FAQ This use case allows to see frequently asked questions page. 
Logout The use case allows USER to log out from the system. By this the USER becomes 
GUEST. 
Profile This use case allows USER to modify his/her profile information. 
Statistics This use case allows USER to see general statistics of his/her activity in the system, i.e. 
the amount of queried done to the system plans. 
Plan Search This use case allows USER to search for necessary plan by specifying search parameters. 
Plan Query This use case allows USER to query a plan to receive annotations. 
Status This use case allows to see the status of query submitted by the USER earlier.  
Results This use case allows to retrieve results of the query (if any) received for the USER's plan 
query. 
GENERAL 
Configuration 
This use case allows to modify various systems parameters. 
GENERAL Update This use case allows to update the system from installation package or patch. 
GENERAL Export This use case allows to create export file for the system that contains all plans, structure 
and data of www and asap tables (for agent_created tables it is only structure). The file is 
to be used in other system to make them absolutely the same as this one. 
GENERAL Import This use case allows MAIN ADMIN to update the system internal data to make it 
completely equivalent to the system the file to import is received from. 
GENERAL Files This use case allows to browse through files of the system and update/delete them. 
GENERAL Statistics This use case allows to see basic statistics for the work of the system for specified period 
of time. 
GENERAL 
Vocabulary 
This use case allows to view/add/modify terms of the system's vocabulary. 
GENERAL 
Documentation 
This use case allows to download the latest ASAP documentation. 
USERS 
Management 
This use case allows to search for a user by name and modify the found user's profile. 
USERS Mass E-mail This use case allows to send mass e-mails to groups of users. 
USERS Banner This use case allows to set text for the banner to be shown in each interface page of the 
system for users to see. 
JOBS Management This use case allows to search started queries by their job identificators and see the status 
of that jobs  
JOBS Agents This use case allows to to run/stop agents launcher - the program that delivers agent 
plans for execution with some periodicity automatically. Also, allows to change original 
parameters of such periodicity for agents and activate or deactivate such agents, or see 
next scheduled time for their execution. 
PLANS Installation This use case allows to install new plans into the system. 
PLANS 
Management 
This use case allows to search for a plan by various criteria and modify the system 
information about the plans. 
PLANS Download This use case allows to download the system plans to the user's desktop. 
PLANS Types This use case allows to add/modify/delete plans types. 
ASAP Installation This use case allows to install all copied (manually into the file system) plans into the 
system. 
ASAP Configuration This use case allows to change ASAP core parameters. 
ASAP Download This use case allows to download the ASAP core modules to users desktop. 
NEVER Uninstall This use case allows for MAIN ADMIN to uninstall the system completely. 
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Figure 21. ASAP deployment diagram. Implementation of ASAP allows to install it as a stand-alone server under 
Apache web server software with Perl language support. Clients access ASAP though web browsers that interact 
with the system web interface. ASAP uses its core functions to access though HTTP, FTP, SMTP, LDAP, SSH 
and other protocols to remote web applications, databases and local algorithms and databases. 
 
 
 
Figure 22 shows schematically a data flow for core ASAP functions that allow a 
user to submit a job to ASAP by querying an annotation plan, to check status of the 
job and to download results of annotations. The system comprises a set of modules 
that handle the generation of queries, parsing of results, formatting final reports, and 
various managerial functions. The user interacts with the system either through a web 
interface or through a configuration file in XML format. The inputs include a gene 
list (typically accession numbers) and a reference to a pre-designed plan for visiting 
multiple web sites. Plans can be easily created by an administrator as needed. The 
JOB MANAGER is a module that uses the database (DB) to generate the plan and 
then passes information to the plan. The Annotation Plan is a Perl script that can also 
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use other Annotation Plans to query local databases and external web resources, 
passing the results of one query to the input of another as necessary. ASAP stores 
received results in output files and information about these files in local database. The 
JOB MANAGER then uses this information to create download links and e-mails this 
information to the user. In case of any external source disruption, an error is 
generated and sent back to the user, while detailed error information is sent to the 
Administrator.  The Administrator is then able to reply quickly to fix the query, if the 
error has occurred because of a change in web formats. 
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Figure 22. Data flow schema for ASAP core functions. JOB MANAGER handles USER’s query request and 
passes input information to Annotation Plan that uses ASAP Package and possibly other Annotation Plans to 
query local Database, external data sources though HTTP or FTP protocol, or local executable algorithms to 
receive results of annotation. USER can check information about submitted job status and download results when 
output files are formed and available. E-mails are used to report results or possible errors to USER and ADMIN.  
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4.3 Automated Sequence Annotation Pipeline annotations 
To support data mining process we created a set of annotation plans for ASAP 
that automatically acquire data required for each step of data analysis. These 
annotations include Affymetrix and Agilent probes identifications, UniGene [160] 
cluster names, descriptions and gene symbols for GenBank accession numbers, gene 
ontology terms and transcription factors for genes. In order to provide results with 
these annotation plans, ASAP uses various external data sources, including 
Affymetrix and Agilent updated slide information, the UniGene database, the Swiss-
Prot protein knowledgebase [112], the Gene Ontology consortium [115] database and 
the professional version of TRANSFAC [161]. 
First, we implemented the UniGene annotation plan for GenBank accession 
numbers that retrieves corresponding information about UniGene cluster ID, gene 
name and description for provided GenBank sequence ID. Gene ontology 
information, such as what molecular function a gene performs, what biological 
process it is involved in and what cellular component it resides in, is also provided for 
the sequence. Figure 23 shows schematically directives for ASAP for the annotation 
plan. The plan is particularly useful for filtering and interpretation of results during 
microarray data analysis.  
ASAP uses regularly updated annotation files from Agilent [162] and 
Affymetrix [163] to identify probes on a slide (assigns GenBank accession numbers) 
and uses UniGene plan to provide UniGene cluster ID, gene name and description 
along with gene ontology for the probe. The information received with this plan can 
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be uses at the first step of microarray data mining process before data pre-processing, 
for example, to filter out probes that do not represent know genes. 
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Figure 23. Schema of UniGene annotation plan. 
 
 
 
Transfac annotation plan annotates each gene with transcription factors that 
regulate that gene. A parameter ‘evidence quality’ is available for specifying to use 
for instance when only experimentally confirmed transcription factor information is 
required. The plan is used to supply modified Bayesian Decomposition with prior 
coregulation information by grouping together genes that have the same transcription 
factor and therefore expected to be co-expressed under specific conditions. 
Specific annotation plans called agents were implemented and used to download 
information from remote sources and put the data into local database in order to 
provide quick and reliable access to necessary data for many other annotation plans. 
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The list of agents is presented in Table 4. Those agents are currently installed to the 
ASAP system and are automatically run by ASAP in specific time intervals as 
indicated in the table to keep the data up to date. The complete list of annotation plans 
of ASAP that use information retrieved by agents are shown in Table 5. 
 
 
Table 4. Agents: annotation plans that acquire information from remote sources and store it locally. 
Agent name Data description Update time          
UG Unigene IDs, gene names and descriptions for Genbank accessions  2 weeks 
SP Gene symbols synonyms information from Swissprot 1 month                  
AF Affymetrix microarray slides information 3 months                
AG Agilent microarray slides information 3 months                
GO Gene ontology information for genes 1 month                  
TF Transcription factors for genes from TRANSFAC Manual update     
 
 
 
Table 5. Annotation plans of the ASAP system 
Plan Description Agent used Plans used 
Unigene Retreives cluster ID, gene name and description for 
genbank accession number 
UG, SP  
Agilent Retreives genebank accession number for Agilent slide 
probes 
AG Unigene 
Affymetrix Retreives genebank accession number for Affymetrix 
slide probes 
AF Unigene 
Accessions Retrieves cluster ID, gene name and description for 
different accession numbers 
 Agilent, 
Affymetrix, 
Unigene 
Ontology Retrieves gene ontology information for any accession 
number 
GO Accessions 
Transfac Retrieves transcription factors for any accession number TF Accessions 
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CHAPTER 5: ANALYSIS OF GASTROINTESTINAL STROMAL TUMORS 
DATA WITH MODIFIED BAYESIAN DECOMPOSITION 
5.1 Data Analysis 
5.1.1 Gastrointestinal Stromal Tumors 
Until recently, there was no effective therapy for advanced, unresectable GISTs. 
Standard sarcoma therapies applied to the patients provided from little to no efficacy. 
A new agent, Gleevec (imatinib, mesylate, STI-571) has been shown to provide a 
significant classic response rate and the majority of patients that were treated with 
Gleevec demonstrated clinical improvement. However, there are cases when patients 
report no response to the treatment with little understanding of the mechanism. 
An ongoing clinical trial at the Fox Chase Cancer Center focused on the effect of 
Gleevec on Gastrointestinal Stromal Tumors (GISTs) recently generated pre- and 
post- treatment samples (53 samples from 25 patients). The experiment is aimed at 
understanding of mechanisms of the disease, and in particular the reason that some 
patients are nonresponders to the treatment. Since imatinib mesylate is known to 
interrupt aberrant signaling in mutated c-KIT (the primary cause of most GIST), the 
lack of response is not well understood.  The goal of this research is determination of 
the reason for treatment failure, whether rescue of the c-KIT pathway downstream of 
c-KIT or activation of other pathways. Identification of the key failure mode may 
identify new therapeutic targets or suggest additional therapeutic approaches.  
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5.1.2 Data from tumors and biopsies 
RTOG S-0132 is a phase II NCI/CTEP approved clinical trial of 
neoadjuvant/adjuvant STI-571 (GLEEVEC NSC #716051) for primary and recurrent 
operable malignant GIST expressing the KIT receptor tyrosine kinase (CD117). 
Patients of 18 years and above, both genders, diagnosed with GIST (biopsy-proven) 
were recruited for the trial. Additional recruitment criteria included 
immunohistochemical documentation of KIT expression in the tumor and no history 
of chemotherapy, radiation therapy, biologic therapy, prior Gleevec. Or other 
investigational drug within 28 days of study entry. 
Protocol of the study implied availability of a biopsy sample of sample before 
registering. The core specimens were obtained with the use of ultrasound, CT scan, or 
endoscopic guidance to assure adequate specimen retrieval in a nonnecrotic area of 
tumor. Patients started taking Gleevec within two weeks following registration. 
Patients stopped protocol treatment if their disease progressed at any time and were 
considered for surgery. The rest of patients underwent surgery after eight weeks of 
starting Gleevec treatment. Default Gleevec dose were set to 600mg per day and were 
modified based on toxicity grades for patients to 400mg (grade 2) or 200mg (grade 3 
or 4) per day. Patients stopped Gleevec the night before surgery and underwent 
standard surgical resection with the objective of surgical debulking and attempt to 
remove all gross disease. 
Experimental samples include biopsies of tumors taken from patients before 
treatment with Gleevec and a portion of the tumor received after dissection surgery 
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(after 3-8 weeks of the treatment started). A total of 50 patients were recruited for the 
study, however only for 25 generated both pre- and post- treatment microarray data 
due to failure to progress to surgery. There are several types of information available 
for each patient: site of tumor origin (stomach, small intestine, colon, or rectum); KIT 
immunohistochemical staining (positive for GISTs); tumor size; mitosis count 
(assessment of malignant potential); histology (spindle, epithelioid, or mixed); and 
risk (high or low, based on tumor size, mitosis count and histology). 
Tumor sizes before (TSB) and after (TSA) treatment were taken to determine 
a relative tumor growth (TG), i.e 
 
TSB
TSBTSATG −=                                                                                (5.1.1) 
Sorted by the tumor growth, patient response data is presented in Figure 24. Patients 
with less than 25% tumor reduction were assigned to non-responders group. Although 
general threshold for clinical response is 30%, this is based on measurement after 12 
weeks on therapy.  Since the time on therapy in this study was only 3-8 weeks, we 
believe that 25% is more appropriate for such a short time span. Another observation 
that favored our choice of threshold is that the first break in the graph of responses 
happens at 25%. 
The protocol for sample preparation for the microarray experiment is shown 
in Figure 25. RNA from both pre- and post- treatment samples was isolated according 
to the method of Chomczynski and Sacchi [164] with modifications. The quality and 
quantity of the total RNA was checked using RNA Nano LabChip® (Agilent 
Technologies) according to the protocol provided. Some RNA samples were purified 
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and DNase treated with RNeasy Micro Kit (Qiagen). 50ng of RNA from the sample 
as well as Human Universal Reference RNA (HUR), Stratagene [165] were amplified 
with Ovation Aminoallyl RNA Amplification and Labeling System (NuGEN 
Technologies, INC).  Amplification products were purified with NucleoSpin Extract 
2 kit, then RNA was dried, dissolved in coupling buffer (0.1M NaHCO3, pH 9.0), 
and stained with Alexa Fluor 555 (HUR) or Alexa Fluor 647 (RNA from patient 
samples) 1 hr at room temperature in the dark. Then this coupling reaction was 
purified with QIAquick PCR purification Kit (Qiagen). 60pmol of patient samples 
versus 60pmal HUR were hybridized on Agilent Human Whole Genome Oligo 44K 
slides (GE2_44k_1005), washed using stabilization and drying solution, and scanned 
with G2565BA scanner (Agilent Technologies), according to manufacture 
specifications. In total, 53 microarray hybridizations have been done, covering 25 
patients with available pre- and post- samples, with 2 patients with replicated post-
treatment samples. 
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Figure 24. Relative tumor growth values. Percent of tumor growth is presented for patients with both pre- and 
post- treatment tumor sizes available. Patient was assigned to non-responders group if tumor reduced for less than 
25%. 
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Figure 25. Preparation of samples for microarray experiment. 50ng of pre- and post- treatment samples were 
amplified and colored with Alexa Fluor 647 (red) and Human Universal Reference mRNA amplified and colored 
with Alexa Fluor 555 (green). Samples were hybridized on 44k human Agilent microarray slides and scanned with 
Agilent feature extraction software. 
 
 
 
5.1.3 Preprocessing of GIST data 
Microarray data provided after scanning of microarray slides was preprocessed 
in several steps. First, we reviewed scatter plots, where expression levels for each 
gene from two channels are plotted against each other. We found unexpected 
irregularities that are shown on plot as two distinct branches (Figure 26, center and 
right plots) in a cloud of expression points. Data from such microarrays were not 
considered for further analysis. After this filtration step, 16 patients had microarray 
data and only 8 of them had both pre- and post- treatment measurements available, 
resulting in total of 24 samples available for the analysis. 
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Figure 26. Example of scatter plots for microarray data from GIST patients. Leftmost figure represent expected 
distribution of expression values. Central and rightmost plots show bifurcation artifact due to errors during 
microarray experiment. 
 
 
 
Data from microarray slides that showed no artifacts were normalized using 
LOWESS [60], with smoothing parameter of 0.7 and no correction for background. 
Probes with saturated signals in at least one channel were removed from slide and 
were not considered with the normalization method. Normalized data from different 
microarray slides was merged together and each probe was assigned with an 
expression value of ratio of experiment channel over control channel. Probes that 
were removed due to saturation in one or two channels were removed from the 
analysis. 
 Next preprocessing step included combining probes that are designed for the 
same sequence, i.e. combine replicates based on GenBank accession numbers 
associated with probes. The mean of expression ratios were taken as a signal and 
standard deviation of the mean as an uncertainty measurement associated with the 
signal. Probes without replicates received an uncertainty measurement of 20% of 
signal, a value based on average uncertainty measurements of replicated probes. 
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 After removing probes that had saturated expression signals and combining 
probes linked to the same accession number together, we obtained a data matrix with 
measurements for genes corresponding to 33029 unique accession numbers.  
5.1.4 Annotations for GIST data 
We used the ASAP system to perform several annotations required for data 
filtering, composition and creation of prior coregulation groups for modified 
Bayesian Decomposition. Transcription factors and gene ontology information also 
was received with ASAP for interpretation of microarray data. GenBank accession 
numbers were used as primal identifiers for sequences represented on microarray 
slides to avoid poor reliability of gene symbols.  
In order to compose data sets for Bayesian Decomposition analysis, we 
performed annotations for all 33029 accession numbers to receive corresponding 
gene information. The UniGene annotation plan (Figure 23) was used from the ASAP 
system to link each accession number to a UniGene cluster, gene name and 
description.  RefSeq (EntrezGene) IDs would be more reliable, however the number 
of such genes is limited.  For further analysis we retained 11733 sequences that were 
found in UniGene database to be linked to a known gene. By this we ensure that we 
analyze signals from sequences that truly represent genes which encode proteins and 
therefore that can be related to biological processes. 
We applied the annotation plan that uses the professional TRANSFAC database 
to retrieve information about known transcription factors that regulate genes 
represented by accession numbers.  A total of 988 genes from the 11733 UniGene 
 75
IDs had information (with the evidence of any quality) available in TRANSFAC at 
the time of the annotation. To generate prior coregulation groups we refined our 
search to pull out information with an evidence quality of 3 or higher, which includes 
transcription factors with functionally confirmed factor binding site (quality 1), 
binding of pure protein (quality 2), and immunologically characterized binding 
activity of a cellular extract (quality 3). Sequence based predictions therefore were 
not included in forming coregulation groups. Table 6 shows 69 groups of genes based 
on common transcription factor that have more than ten members in each. Among 
631 unique genes that formed these groups, only 311 were represented in a single 
unique group, and others were regulated by more than one transcription factor. The 
amount of such genes reflects present knowledge about multiple regulations, and 
even those 311 single grouped genes are likely to have multiple transcription factors. 
We used 69 coregulation groups as prior information to include into analysis by 
Bayesian Decomposition. 
5.1.5 Dataset composition 
There are several important questions that can potentially be addressed by 
analysis of the described GIST data. First, genes that are biological markers of patient 
response to Gleevec treatment is of a special interest, since they can be used as a 
predictors of treatment efficacy. Second, analysis of the GIST microarray data can 
determine activity of transcription factors that differ between responders and non-
responders. While biological markers can provide us with indicators of the disease, 
estimations of the activity of transcription factors can help in determining activity of 
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upstream signalling pathways and therefore in revealing of mechanisms of resistance 
to the treatment. To address these different questions we created two separate data 
sets that are designed to take advantage of the data in order to isolate the problems of 
interest. 
 
 
Table 6. Coregulation groups based on transcription factors for GIST data set. 
# TF Total genes 
Shared
genes # TF 
Total 
genes 
Shared
genes # TF 
Total 
genes 
Shared
genes 
1 STAT5B 10 10 24 HMG I 13 13 47 NF-IL6-2 20 14 
2 RAR-β 10 9 25 STAT5A 13 11 48 COUP-TF1 21 20 
3 Nkx2-1 10 7 26 NF-AT1 13 12 49 HNF-1α-A 21 15 
4 AhR:Arnt 10 2 27 IRF-1 14 6 50 COUP-TF2 21 20 
5 GATA-6 10 9 28 p50 14 14 51 YY1 21 18 
6 POU2F1 10 7 29 c-Myc 14 6 52 Gfi1 21 10 
7 IPF1 10 7 30 c-Ets-1 14 8 53 RXR-α 22 19 
8 NF-YB 10 9 31 ATF-2 15 12 54 GR 22 16 
9 LXR-α:RXR-α 10 7 32 STAT1 15 14 55 HNF-3β 23 23 
10 HSF2 11 11 33 GATA-1 16 3 56 HIF-1 24 12 
11 NRSF 11 6 34 NF-YA 16 13 57 Egr-1 24 20 
12 MyoD 11 6 35 GATA-4 16 14 58 ER-α 26 18 
13 GLI1 11 4 36 Pax-6 16 2 59 HNF-4α1 28 26 
14 HSF1 (long) 12 12 37 C/EBPδ 17 17 60 USF1 29 26 
15 HNF-6α 12 12 38 STAT3 17 12 61 NF-κB 29 26 
16 HNF-3α 12 12 39 LEF-1 17 7 62 HNF-4 29 21 
17 E2F-1 12 7 40 c-Fos 18 18 63 SRF 31 24 
18 HNF-6β 12 12 41 C/EBPβ 18 18 64 c-Jun 38 36 
19 T3R-α 12 8 42 NF-Y 19 13 65 Sp3 45 37 
20 T3R-β1 12 10 43 AP-2αA 19 17 66 CREB 45 32 
21 JunD 12 12 44 HNF-4α 19 13 67 AP-1 48 41 
22 E12 12 9 45 RelA 19 19 68 C/EBPα 52 47 
23 JunB 12 12 46 USF2 20 19 69 p53 71 24 
 
 
 
The first data set (named the biomarkers data set) comprised genes that were 
significantly differentially expressed between responders and non-responders, where 
threshold for non-responders group was defined as shown in Figure 24. We applied 
significance analysis of microarrays (SAM) [80] to the expression data of 11733 
annotated genes and received a list of 581 genes that were significantly different 
between two patient groups with a false discovery rate of 13%. Out of pre- and post- 
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treatment samples of 16 patients, samples of patients 10, 13, 28, 29, 34, 41 and 50 
were in the group of non-responders, samples of patients 01, 03, 09, 12, 19, 22 and 45 
were in the group of responders, and samples of patients 08 and 23 were unclassified, 
since no data about tumour size after treatment were available for these patients at the 
time of the analysis. The final data matrix consisted of measurements of 581 genes 
across 24 samples. 
The second data set (named the transfac data set) comprised 988 genes that 
had annotations from the professional TRANSFAC database with any evidence 
quality. Designed to determine activity of transcription factors and possibly of an 
upstream signalling pathway, the final data matrix comprised expression levels of 988 
genes across 24 samples. 
5.1.6 BD analysis 
We analyzed the biomarkers dataset using Bayesian Decomposition without any 
prior coregulation information included in the analysis, since it was not enough 
information of verified transcription factors for 581 genes that were included in the 
data set. 9 separate Bayesian Decomposition instances were run positing from 2 to 10 
patterns to cover the possible dimensionality of the data. The transfac data set was 
analyzed with modified Bayesian Decomposition using coregulation groups from 
Table 6 as prior information for the analysis. BD was run positing from 5 to 15 
patterns, covering more solutions than for the biomarkers dataset to account for 
patterns that do not relate to patient response, since the data were not filtered based 
on expression profiles of the included genes and therefore contained more diversity. 
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5.2 Results 
5.2.1 Methods of result interpretation 
There are several steps in interpretation of the results received with Bayesian 
Decomposition. First, an issue of determining a correct number of patterns in the 
analyzed data requires a solution. Once the number of patterns is determined, 
amplitude and pattern matrices should be analyzed to reveal patterns that represent 
meaningful expression changes and groups of genes that belong to such patterns. 
Then, groups of genes are investigated to see if they possess any distinctive features, 
for example, by comparing portion of genes from the group involved in a certain 
biological process to the portion of such genes from the whole dataset (refer to 
equation 5.2.1). 
The problem of defining a correct number of expression patterns that exist in the 
data can be addressed by looking at the persistence of patterns across results with 
different numbers of patterns posited in the analysis. The persistence of a pattern can 
be defined as the number of consecutive times that a pattern is found by BD as we 
increase the number of posited patterns. Therefore, one would expect average 
persistence to decline monotonously with increased number of patterns. A point, after 
which monotony is broken by sudden drop in average persistence of found patterns, 
would indicate an optimal number of expression patterns in the data. That is, giving 
unneeded degree of freedom to the model results in a set of patterns that lack 
consistency. 
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The goal of the GIST data analysis focuses on patient response to Gleevec 
treatment. Therefore, the main criterion of interest for patterns is a correlation of gene 
expression with observed response. Other possible biologically meaningful patterns 
include correlation with patient’s gender, age, origin of a tumor, etc. 
The amplitude matrix can be used to see what genes contain patterns of interest 
and group those genes together to perform enhancement analysis of the group. 
Enhancement of a term in a group is a measure of presence of the members annotated 
with the term in the group compared to presence of the term in the whole data, i.e.: 
data
total
data
term
group
total
group
term
term NN
NNE
/
/=                                                                        (5.2.1) 
where Nterm is a number of genes annotated with the term in the group or in the whole 
data and Ntotal is a number of all genes in the group or in the whole data. Thus, 
enhancement can provide interpretation for a group of found co-expressed genes and 
assign biological meaning to the expression pattern by monitoring properties of genes 
that contain the pattern. 
5.2.2 Biomarkers data set 
We analyzed the biomarkers data set using Bayesian Decomposition without 
prior coregulation information included into analysis. First, we calculated average 
persistences for different number of solutions (patterns) posited into analysis. Based 
on the graph shown in Figure 27, we picked 7 patterns as the optimal number of 
expression patterns for analysis of the data. 
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Figure 27. Average persistences of patterns for different number of solutions posited into analysis in biomarkers 
data set. When increasing number of patterns from 7 to 8, the curve drops faster than expected indicating that 
increasing number of solution after 7 results in relatively non-stable patterns.  
 
 
 
All 7 expression patterns from the pattern matrix recovered by Bayesian 
Decomposition were used to calculate correlation coefficients with patient response. 
Two patterns with absolute correlation coefficients >0.7 were found, pattern 4 being 
positively correlated with response with value of correlation R=0.702 and pattern 7 
being negatively correlated with response with value of correlation R=-0.786. Figure 
28 shows those patterns. Based on the expression values related to unclassified 
patients 08 and 23 in recovered patterns linked to patients’ response, we concluded 
that both patients 08 and 23 should belong group of responders.  We will use these 
predictions as a validation point of our analysis, when true information about the 
response is received. 
The Amplitude matrix from the Bayesian Decomposition analysis was used to 
assign genes to patterns 4 and 7. Each gene in the amplitude matrix had a mean value 
of its strength within a pattern and an uncertainty on that assignment based on the 
MCMC sampling performed by BD. We used a threshold of 3 standard deviations 
away from zero as a requirement to assign a gene to a pattern, which resulted in a 
group of 194 genes that contained pattern 4 and 46 genes that contained pattern 7. 
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Pattern 7 of 7: R = -0.785
0.00E+00
2.00E-02
4.00E-02
6.00E-02
8.00E-02
1.00E-01
1.20E-01
1.40E-01
1.60E-01
19
_p
st
_R
09
_p
st
_R
01
_p
st
_R
45
_p
re
_R
45
_p
st
_R
12
_p
re
_R
12
_p
st
_R
22
_p
re
_R
22
_p
st
_R
03
_p
re
_R
03
_p
st
_R
28
_p
re
_N
28
_p
st
_N
50
_p
re
_N
50
_p
st
_N
13
_p
re
_N
10
_p
re
_N
34
_p
st
_N
29
_p
re
_N
29
_p
st
_N
41
_p
st
_N
08
_p
re
08
_p
st
23
_p
st
RESPONDERS NON-RESPONDERS unclassif ied
 
Figure 28. Expression patterns found by Bayesian Decomposition in biomarkers data set. Figure on the top shows 
pattern positively correlated (R=0.702) with response (genes are upregulated in responders compared to non-
responders). Figure on the bottom shows pattern negatively correlated (R=-0.785) with response (genes with such 
expression pattern are downregulated in responders compared to non-responders).  
 
 
 
We performed enhancement analysis of gene ontology terms for these groups 
of genes based on annotations from the ASAP system. Table 7 and Table 8 represent 
gene ontology enhancements of 1.5 and above for the groups of genes that contain 
expression pattern 4 and pattern 7 respectively. 
 
 
Table 7. Table of gene ontology term enhancements for the pattern correlated with response. 
Gene Ontology Biological Process Enhancement Ntermgroup Ntermtotal
GO:0006935 chemotaxis 2.62 7 8 
GO:0042330 taxis 2.62 7 8 
GO:0042221 response to chemical substance 2.00 8 12 
GO:0016337 cell-cell adhesion 1.91 7 11 
GO:0001501 skeletal development 1.87 10 16 
GO:0019725 cell homeostasis 1.87 5 8 
GO:0006118 electron transport 1.83 11 18 
GO:0042592 homeostasis 1.66 5 9 
GO:0006643 membrane lipid metabolism 1.66 5 9 
GO:0009628 response to abiotic stimulus 1.65 11 20 
GO:0030029 actin filament-based process 1.63 6 11 
GO:0030036 actin cytoskeleton organization and biogenesis 1.63 6 11 
GO:0043067 regulation of programmed cell death 1.61 7 13 
GO:0042981 regulation of apoptosis 1.61 7 13 
GO:0000004 biological process unknown 1.59 9 17 
GO:0006091 generation of precursor metabolites and energy 1.56 13 25 
GO:0007155 cell adhesion 1.54 20 39 
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Table 8. Table of gene ontology term enhancements for the pattern correlated with nonresponse. 
Gene Ontology Biological Process Enhancement Ntermgroup Ntermtotal
GO:0042127 regulation of cell proliferation 3.16 5 20 
GO:0048522 positive regulation of cellular process 2.44 6 31 
GO:0051242 positive regulation of cellular physiological process 2.43 5 26 
GO:0008283 cell proliferation 2.39 7 37 
GO:0048518 positive regulation of biological process 2.37 6 32 
GO:0043119 positive regulation of physiological process 2.34 5 27 
GO:0043118 negative regulation of physiological process 1.97 5 32 
GO:0051243 negative regulation of cellular physiological process 1.97 5 32 
GO:0007165 signal transduction 1.90 19 126 
GO:0007242 intracellular signaling cascade 1.80 6 42 
GO:0048523 negative regulation of cellular process 1.80 5 35 
GO:0048519 negative regulation of biological process 1.75 5 36 
GO:0030154 cell differentiation 1.75 5 36 
GO:0007166 cell surface receptor linked signal transduction 1.64 7 54 
GO:0045184 establishment of protein localization 1.62 5 39 
GO:0008104 protein localization 1.62 5 39 
 
 
 
5.2.3 Transfac data set 
The transfac data set was analyzed using modified Bayesian Decomposition with 
prior coregulation information from Table 6 included into analysis. Similar to 
biomarkers data set, we calculated average persistences for different number of 
solutions posited into analysis and average persistence plot dropped after 9 patterns as 
demonstrated in Figure 29. After this step we analyzed pattern and amplitude 
matrices recovered by modified BD with 9 patterns posited into decomposition 
process. 
Two basic steps were performed for each pattern and corresponding group of 
genes that contained the pattern. First, 3 correlation values of a pattern with response 
of only pre- treatment samples, only post-treatment samples and all samples were 
calculated. Second, we performed transcription factors and gene ontology term 
enhancement analysis for all groups, using ASAP annotations from the professional 
TRANSFAC database and the Gene Ontology Consortium database. Only 
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information that had qualities of evidence of 1, 2 and 3 were used for transcription 
factor enhancement analysis. A gene was assigned to a pattern if corresponding mean 
value (sampled during MCMC process) from amplitude matrix satisfied the condition 
to be of 3 standard deviations above zero. 
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Figure 29. Average persistences of patterns for different number of solutions posited into analysis in Transfac data 
set. 
 
 
 
Although correlations calculated for all samples of nine patterns received 
from analysis of the Transfac data set didn’t indicate strong link with the response as 
can be seen in column 4 of Table 9, we decided to focus on specific patterns that 
indicate connection to response for specific pre- or post- treatment samples (columns 
2 and 3 of Table 9). Thus, patterns with positive and negative correlation values of 
magnitude 0.4 and above were chosen for further analysis. Correlation of a pattern’s 
pre-treatment samples with response can indicate differences in activity of 
transcription factors and upstream signalling pathways between two groups of 
patients before starting therapy.  Markers of response can help in identifying of 
underlying mechanisms lying behind the difference. Similarly, patterns with post-
treatment samples linked to outcome can be treated as biological processes 
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differentially expressed between responders and non-responders due to introduction 
of Gleevec into the system. Potentially these can help in identifying signalling 
pathways that lead to rescue of cancer cells in non-responsive patients, providing 
additional therapeutic targets. 
 
 
Table 9. Correlation with response for patterns found in Transfac dataset. Different columns show correlations for 
specific expression values from patterns that correspond to different sample types. Correlations of absolute value 
>0.4 are marked in bold italic. 
Pattern 
Only pre-
treatment 
samples 
Only post-
treatment 
samples 
Both, pre- and 
post-treatment 
samples 
1 of 9 -0.01 -0.35 -0.19 
2 of 9 -0.26 0.54 0.38 
3 of 9 0.01 0.16 0.14 
4 of 9 0.47 0.07 0.21 
5 of 9 -0.05 -0.41 -0.23 
6 of 9 0.12 0.20 0.09 
7 of 9 -0.27 0.41 -0.14 
8 of 9 -0.12 -0.29 -0.21 
9 of 9 -0.58 -0.04 -0.15 
 
 
 
Table 10 demonstrates enhancement analysis results for the patterns 2,4,5,7 
and 9 that showed correlations of pre- or post- samples with response. In order to 
avoid false positive errors, results were filtered to include only such terms that are 
represented within 4 or more members of a pattern and showed two-fold 
enhancement. Results of enhancement analysis of associated with genes transcription 
factors are reported in Table 11 (pattern 7 did not show significant enhancements). 
Even more stringent filtering criteria were applied to the results. Only greater than 
two-fold enhanced transcription factors are reported with 4 or more members 
presented in the group. Plus, threshold of 5% was chosen as a maximum probability 
for reported transcription factor to be found randomly. Probabilities of error were 
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calculated based on hypergeometric distribution, i.e. probability P of grouping 
together exactly x of a possible K genes annotated with a given transcription factors 
in a group of M genes from total number of N genes (988 for the Transfac data set), 
i.e. 
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Table 10. Enhancements of biological process GO terms for groups of genes with selected from Transfac data set 
patterns. 
Gene Ontology term Enhancement Ntermgroup Ntermtotal
 
Pattern 2 (for post-treatment samples correlation with response R=0.54), 129 genes 
GO:0044257 - cellular protein catabolism 2.55 4 12 
 
Pattern 4 (for pre-treatment samples correlation with response R=0.55), 78 genes 
GO:0006366 - transcription from RNA polymerase II promoter 5.43 6 14 
GO:0008285 - negative regulation of cell proliferation 2.53 5 25 
 
Pattern 5 (for post-treatment samples correlation with response R=-0.41), 97 genes 
GO:0008610 - lipid biosynthesis 2.72 4 15 
GO:0006811 - ion transport 2.04 5 25 
GO:0006066 - alcohol metabolism 2.04 4 20 
 
Pattern 7 (for post-treatment samples correlation with response R=0.41), 63 genes 
GO:0009628 - response to abiotic stimulus 2.61 4 24 
 
Pattern 9 (for pre-treatment samples correlation with response R=-0.58), 95 genes 
GO:0050790 - regulation of enzyme activity 4.16 4 10 
GO:0006520 - amino acid metabolism 2.77 4 15 
GO:0044249 - cellular biosynthesis 2.21 7 33 
GO:0006519 - amino acid and derivative metabolism 2.17 5 24 
 
 
 
 
 86
Table 11. Enhancements of transcription factors for groups of genes with selected from Transfac data set patterns. 
Transcription Factor term Enhancement Ntermgroup Ntermtotal Random? 
 
Pattern 2 (for post-treatment samples correlation with response R=0.54), 129 genes 
KCHIP2.6 6.13 4 5 0.122% 
CSEN 6.13 4 5 0.122% 
c-Jun:c-Fos 5.96 7 9 0.002% 
STAT3 4.25 5 9 0.260% 
HMG I 3.48 5 11 0.727% 
AP-1 3.48 5 11 0.727% 
LXR-alpha:RXR-alpha 3.4 4 9 1.780% 
NF-Y 3.4 4 9 1.780% 
STAT1 3.06 6 15 0.667% 
p50 2.55 4 12 4.638% 
c-Jun 2.14 7 25 2.411% 
SRF 2.09 6 22 3.851% 
 
Pattern 4 (for pre-treatment samples correlation with response R=0.55), 78 genes 
VDR 7.24 4 7 0.100% 
STAT3 5.63 4 9 0.308% 
STAT1 4.22 5 15 0.376% 
RXR-alpha 4 6 19 0.202% 
c-Myc 3.9 4 13 1.275% 
SRF 3.38 4 15 2.078% 
p53 2.49 12 61 0.132% 
 
Pattern 5 (for post-treatment samples correlation with response R=-0.41), 97 genes 
Max1 10.19 5 5 0.001% 
STAT3 4.53 4 9 0.673% 
c-Myc 3.92 5 13 0.485% 
NF-Y 3.4 4 12 1.958% 
p53 2.91 4 14 3.241% 
RXR-alpha 2.68 5 19 2.415% 
Gfi1 2.55 5 20 2.914% 
 
Pattern 9 (for pre-treatment samples correlation with response R=-0.58), 95 genes 
AFP1 10.4 4 4 0.008% 
HNF-1alpha-B 10.4 6 6 0.000% 
HNF-1alpha-C 10.4 6 6 0.000% 
c-Jun:c-Fos 6.93 6 9 0.004% 
HMG I 4.73 5 11 0.193% 
HNF-4alpha 4.33 5 12 0.301% 
AP-1 3.78 4 11 1.347% 
HNF-1alpha-A 3.47 7 21 0.191% 
HNF-3beta 3.31 7 22 0.255% 
HNF-4 3.25 5 16 1.127% 
 
 
 
5.2.4 Comparison of results recovered from Transfac data set with modified and 
original Bayesian Decomposition 
Comparison of results of analysis for two algorithms without knowing correct 
answers is a nontrivial task. We ran original BD positing 9 patterns into analysis 
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without including any additional knowledge. Similarly to results of modified BD, 
correlation coefficients of recovered patterns with response were calculated and 
enhancement analysis of transcription factors performed according to protocol 
described in Section 5.2.3. 
All correlation coefficients with response for patterns received by original and 
modified BD were compared. Average absolute difference for all correlation 
coefficients as well as only for above threshold values (|correlation|>0.4) was less 
than 5% of average correlation magnitude for each of the methods, indicating 
insignificant difference between recovered expression patterns. However, amount of 
genes assigned to these patterns varied greatly, with modified Bayesian 
Decomposition assigned 462 genes to significant patterns 2, 4, 5, 7 and 9 (129, 78, 
97, 63 and 95 genes respectively), while original Bayesian Decomposition had a 
statistical power to assign only 385 genes (90, 72, 94, 65 and 64 genes) to these 
patterns, a drop of 17%.  It appears therefore that the modified version of BD is using 
prior information to increase the linking of genes to patterns, as desired. On contrary, 
insignificant patterns 1, 3, 6 and 8 were assigned with 225 by modified BD and 331 
genes by the original BD. 
Enhancement analysis performed for gene groups revealed consequences of the 
lack of statistical power to assign genes to a pattern for original Bayesian 
Decomposition. Pattern 4 did not indicate activity of VDF, and significance of 
enhancement of activity of the transcription factor Max1 was lost for Pattern 5. 
Additionally, we compared amount of genes related to significantly enhanced 
transcription factors (enhancement greater than 2.0, with 4 or more members 
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presented in the group) recovered from results received with and without using prior 
coregulation information. Number of enhanced terms, grouped and total number of 
genes with these terms for significant patterns 2, 4, 5, 7 and 9 for both methods are 
shown in Table 12. The table accounts for more terms than Table 11, since it also 
contains terms that do not satisfy 5% error rate threshold. Those results indicate that 
using coregulation information to overcome the low signal-to-noise ratio of 
microarray data on average helped in recovering of ~34% of group members, while 
algorithm without using such information produced coverage of only ~24%.  
 
 
Table 12. Comparison of number of genes with enhanced terms from results received with and without using 
coregulation information. 
 Using coregulation Without coregulation 
 
Number of 
enhanced 
terms 
Genes with 
the terms in 
the group 
Genes with 
the terms in 
the data 
Number of 
enhanced 
terms 
Genes with 
the terms in 
the group 
Genes with 
the terms in 
the data 
Pattern 2 14 69 171 11 52 206 
Pattern 4 9 47 183 2 13 74 
Pattern 5 9 40 130 1 4 20 
Pattern 7 0 0 0 0 0 0 
Pattern 9 12 68 177 4 18 56 
Average 
recovery 
of genes 
34% 24% 
 
 
 
5.2.5 Discussion 
Two expression patterns found in the biomarkers data set were linked to patient 
outcome. Pattern 4, which showed positive correlation with response, included 194 
genes. The list of 42 genes with >90% of their behavior explained solely by pattern 4 
was investigated further to look for connections with previous studies. Figure 30 
shows an amplification of chromosomal region 6p21 found in an independent study 
 89
of DNA mutations in GIST patients by Dr. Godwin’s lab at the Fox Chase Cancer 
Center. Chromosome locations of 3 genes, SRF, MAD2L1 and VEGF, with 
respectively 97%, 91% and 95% expression profile explained by pattern 4, lie in the 
region. Further inspection of the list of genes with expression pattern 4 yielded one 
more gene, BYSL, which resides near the region. Unfortunately, because no outcome 
data was available for the patients that show such DNA mutation, we could not 
validate importance of these four genes in prediction of the response. 
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Figure 30. Chromosome copy analysis of cytoband 6p21 for GIST patients from different study. Common 
amplification region in shown on the figure. BYSL, SRF, MAD2L1, VEGF – genes than have expression profiles 
explained by pattern 4 for 70%, 97%, 91% and 95% respectively.  
 
 
 
Gene ontology enhancement analysis of the genes that contain pattern 4 and 
pattern 7 was performed to search for biological significance of the patterns. One of 
several significant enhancements for pattern 4, presented in Table 7, included cell 
adhesion related biological processes that are known to be mutated in some cancers, 
resulting in abnormal cell-to-cell interactions and tumor growth. Another difference 
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between responders and non-responders was in regulation of apoptosis, most 
probably related to higher apoptosis after Gleevec treatment, responsible for the 
observed difference in patient outcomes. Gene ontology enhancements for the group 
of genes with expression pattern 7, which is negatively correlated with response, also 
followed the prediction model. Marked with italic font in Table 8, cell proliferation 
and differentiation processes are overrepresented in non-responders compared to 
responders, indicating tumor growth or smaller size reduction of tumors in patients 
that do not respond to the imatnib. 
After analysis of the biomarkers data set we received missing data for post-
treatment tumor sizes of patients 08 and 23. The data for patients 08 and 23 showed 
response of 39% and 27% tumor reduction size respectively. Thus, the prediction we 
made based on the relative expression levels for samples 08_pre, 08_pst and 23_pst 
in both pattern 4 and pattern 7, validated successfully, providing confirmation of 
prediction of response made by these patterns. 
Analysis of the genes with known transcription factors revealed expression 
patterns that were linked to the response based on correlations of only pre- or post- 
treatment samples with outcome. From nine patterns, with the number of patterns 
determined by analysis of average pattern persistences, five showed correlations with 
tumor reduction. 4 of these patterns, namely pattern 2, pattern 4, pattern 5 and pattern 
9 showed significant (hypergeometric based error rate <5%) enhancements of several 
transcription factors as demonstrated in Table 11. 
Pattern 2 showed positive correlation with response for post-treatment samples 
(R=0.54). Significant enhancements of gene ontology terms included only non-
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informative biological processes of a metabolic nature. Activity of such transcription 
factors as KCHIP2.6 (also called FOSL2), which had an enhancement of 6.13, 
belongs to family of FOS genes and encode leucine zipper proteins that can dimerize 
with proteins of the JUN family, forming the transcription factor complex AP-1. 
Activity of AP-1 was also determined for the pattern2, along with the c-Jun:c-Fos 
complex, which is another instance of AP-1 transcription factor. The activity of these 
transcription factors demonstrate cancer-related biological processes as FOS proteins 
have been implicated as regulators of cell proliferation, differentiation, and 
transformation. 
Another group of transcription factors activated according to expression pattern 
2 that reflects response in post-treatment samples consist of serum response factor 
(SRF) and STAT1/STAT3 genes, also represented in pattern 4 with pre-treatment 
samples correlated to response (R=0.55). It is known that both STAT1/STAT3 and 
SRF contribute to c-fos promoter activation [166] and thereby participates in cell 
cycle regulation, apoptosis, cell growth, and cell differentiation processes. 
Some of the genes that contain pattern 4 are also regulated by vitamin D receptor 
(VDR) that showed enhancement of 7.24 and is known to inhibit growth of breast 
cancer cells [167, 168]. Since pre-treatment samples of pattern 4 positively correlated 
with response, we can predict that the activity of signalling pathway that regulates 
VDR potentially aids in inhibition of GIST cell growth after therapy with Gleevec. 
Another conclusion can be drawn for the pattern 4 from enhancement of negative 
regulation of cell proliferations gene ontology term (Table 10). It indicates presence 
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of genes that contribute to inhibition of cell proliferation in most responders, but not 
in non-responders. 
Pattern 5 demonstrated negative correlation of post-treatment samples with 
response (R=-0.41), meaning that genes included in the group are more expressed in 
post-treatment samples of responders compared to non-responders. More than ten-
fold enhancement of genes regulated by Max1 is given in Table 11 with 5 of total 5 
genes from the data set grouped by Bayesian Decomposition. Max1 is a 
heterodimeric partner of c-Myc that allows self dimerization. While Myc-Max 
compound activates transcription to promote apoptosis, Max-Max may repress it due 
to lack of a transcriptional activation domain [169, 170]. Such behavior of Max1 is 
perfectly explained within the model – expression levels of Max1 genes that contain 
pattern 5 are higher in non-responders (post-treatment samples) indicating activity of 
Max1 that rescues GIST sells from apoptosis. 
Pattern 9 with pre-treatment samples correlated negatively with response (R=-
0.58) showed greater than ten-fold enhancements for two transcription factors, AFP1 
and HNF-1alpha (target genes for HNF-1alpha-B and HNF-1alpha-C were the same, 
so do not allow separation of these three transcription factors). Both AFP1 and HNF1 
are known to have important biological role in carcinomas, with AFP1 activity linked 
to hepatocellular carcinoma in liver [171, 172] and HNF-1alpha loss of function in 
renal cell carcinoma [173]. 
One of the results that bind biomarkers and transfac data together is a recovery 
of a transcription factor SRF in both analyses. Shown to be amplified in some GIST 
patients (Figure 30), SRF was assigned to the pattern 4 of 7 for the biomarkers data 
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set, which was positively correlated with response to Gleevec treatment. As expected, 
activity of the SRF transcription factor was confirmed during analysis of the transfac 
data set. Groups assigned to patterns 2 and 4, which were also positively correlated 
with response in pre- and post- treatment samples, demonstrated enhancement of the 
SRF transcription factor regulated genes in these groups. While the probability of the 
results to be a false positive error cannot be ignored, prediction validation and various 
confirmations of biological meaning of recovered patterns related to SRF strongly 
suggest importance of the gene in GISTs and provide an important validation 
checkpoint to our designed data mining approach.  
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CHAPTER 6: CONCLUSIONS AND REMARKS 
6.1 Conclusions 
This study introduced a data mining process for analysis of high-throughput 
biological data, initially microarray data, that allows the inclusion of prior biological 
information to allow data integration and reduce the impact of noisy data. The core 
technique is the Bayesian Decomposition algorithm. Bayesian Decomposition uses a 
Markov Chain Monte Carlo sampler with Bayesian statistics that provides a 
mechanism for encoding prior knowledge into the process. A modification for the 
algorithm has been implemented that enables using known information about gene 
coregulation in the model. Such coregulation information along with annotations for 
all genes that are also necessary in the data mining process can be found in various 
databases with web-based access, but collecting this information can be time 
consuming and involve multiple steps before the data is presented in a specific usable 
form. To automate the process of data collection we created the Automated Sequence 
Annotation Pipeline system that allows customized annotation of data. 
The data mining process was applied to analysis of Gastrointestinal Stromal 
Tumor data as shown on Figure 31. The data set analysis focused on the effects of 
Gleevec treatment on patients and mechanisms of difference in response to the drug. 
ASAP system and modified Bayesian Decomposition were used as a part of the 
microarray data analysis process and results were interpreted with received 
annotation information about transcription factors and gene ontology of genes under 
study. 
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Figure 31. Summary of thesis contributions. GIST microarray data was pre-processed, annotated with ASAP 
system, analyzed by modified Bayesian Decomposition, which was validated on simulated and well-studied yeast 
data sets, and the results were interpreted using annotation information.  
 
 
 
6.1.1 Modified Bayesian Decomposition 
This thesis focused on creating a modified Bayesian Decomposition approach 
that allows encoding of prior coregulation information into analysis. We created 
convolution function that spreads atoms from one part of atomic domain into multiple 
amplitude matrix elements that correspond to a group of coregulated genes as 
described in Section 3.1. A normalization issue of genes having different expression 
levels was solved by applying additional step of Bayesian Decomposition analysis to 
determine weights for each gene in each group of co-expression (Figure 12). 
Validation of modified Bayesian Decomposition was first performed on 
simulated data modeling yeast cell-cycle expression data. Multiple data sets were 
created with 154 different combinations of additive and multiplicative noise levels 
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that reflect low signal-to-noise ratio of real microarray measurements. In Section 3.2 
we showed that including of prior knowledge into analysis improves quality of the 
received results. A significance of amount of such prior knowledge was also 
demonstrated by comparing results between different levels of prior included into 
analysis as shown in Figure 15. 
The second step of validation of enhancements done to Bayesian Decomposition 
was done by analyzing real biological microarray data – yeast cell-cycle data set [90] 
and yeast mutant Rosetta Compendium data set [153]. ROC analysis (Section 3.2.1) 
was used for the purpose of comparing original and modified Bayesian 
Decomposition. Both data sets confirmed advantages of using prior coregulation 
information when compared by ROC analysis with a golden standard that comprises 
the same information (left Figure 17, Figure 18). A different golden standard based 
on groups of Cherepinky et al. [94], was used for ROC analysis of yeast cell-cycle 
results where there was no difference in recovering of the golden standard 
information between original and modified Bayesian Decomposition. This result 
demonstrates present limits on coregulation knowledge, since only 67 from 788 genes 
had prior information associated with them and that wasn’t enough to provide a 
significant difference in the results. Nevertheless, we also compared Bayesian 
Decomposition algorithm to hierarchical and k-means clustering. The results of the 
comparison shown in Figure 17 (hierarchical clustering) and Figure 18 (k-means 
clustering) suggest that important ability of Bayesian Decomposition to allow 
assignment of one gene to multiple patterns of expression is superior to clustering 
approach of one gene to one cluster membership. 
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6.1.2 Automated Sequence Annotation Pipeline 
The Automated Sequence Annotation Pipeline was created to allow customized 
annotation that can query various sources including remote and local databases, and 
take output from one query as the input for a new query (Chapter 4). User and 
administrator oriented web interface of the system was designed to simplify access of 
users to annotation plans of the system and received results and provide 
administrators with tools to manage users, annotation plans and messaging system 
that alarms about errors due to changes of format of data provided by independent 
sources of annotations. ASAP was implemented and installed in Fox Chase Cancer 
Center allowing access of researchers of the institution to aid in studies by providing 
various annotations. 
Several annotation plans were designed to support the data mining process 
described in this thesis support at all steps of the analysis as depicted in Figure 4. 
Probe annotation plans are available for Agilent and Affymerix platforms allowing 
access to constantly updated microarray slides information for these systems. 
UniGene annotation plan was created for receiving cluster ID, gene name and 
description for GenBank accession numbers and used for analysis of GIST data set 
for filtering and data composition steps (Section 5.1.3). Gene ontology and 
transcription factors information for genes can be also received by annotation plans 
implemented within ASAP system. We successfully used these annotations to create 
prior information, presented in Table 6, for analysis of GIST data set with modified 
Bayesian Decomposition. Finally, enhancement analysis of the groups of genes 
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received from GIST data set was performed using gene ontology and transcription 
factors annotation information. 
6.1.3 Analysis of Gastrointestinal Stromal Tumors 
The central study of Gastrointestinal Stromal Tumors data was preformed 
according to the developed data mining process. Annotations received with ASAP 
system were used at different steps of the analysis as described in Section 5.1.3, 
including gene filtering, data composition, prior information generation and gene 
enhancement results analysis. Data composition step resulted in generating two 
separate data sets that were designed to carry out two different tasks: to find genes 
that can serve as biomarkers to predict patients response to Gleevec and to determine 
activity of transcription factors that can explain difference in such a response.  
The biomarkers data set revealed genes that contain expression patterns 
correlated with patients’ response. Two groups of 194 and 47 genes were found that 
had a correlation with response of 0.702 and -0.785 respectively. Gene ontology 
enhancements analysis was performed to see the biological processes that these genes 
were involved in. Positively correlated with response patterns showed biologically 
meaningful enhancements of cell apoptosis processes, indicating higher rate of cell 
deaths in responders to Gleevec treatment. On contrary, pattern that showed more 
expression in non-responders, revealed enhanced biological processes of cell 
proliferation and differentiation, which can be related to slower size reduction of 
tumor or even tumor growth in non-responsive patients. Finally, predictions made for 
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patients 08 and 23 to be responders were confirmed as correct with the later received 
missing outcome data. 
The second data set revealed activity of various transcription factors that can be 
linked to patients response based on sample before and after Gleevec treatment. SRF 
transcription factor determined by the analysis of biomarkers dataset to be 
upregulated in responders compared to non-responders, also showed increased 
activity in responders in both pre- and post- treatment samples. Another transcription 
factor, Max1, showed activity enhancement of more than 10-fold with negative 
correlation to response in post-treated samples. Known to have and ability to rescue 
endothelial cells from apoptosis, Max1 can be involved in similar mechanisms in 
GISTs, allowing tumor grow after being introduced with Gleevec. Also, activity of 
vitamin D receptor, VDR, transcription factor was demonstrated on its target genes to 
be more active in responders than in non-responders in pre-treatment samples. 
Combined with information from other studies, where activation of VDR was shown 
to inhibit growth of breast cancer cells, we can hypothesize about positive role of 
VDR during treatment of GISTs with imatinib. 
Transfac data set was also analyzed with Bayesian Decomposition without any 
prior information included into the model. Comparisons of results were performed 
and revealed that original Bayesian Decomposition recovered 17% less genes for 
linked to response patterns 2, 4, 5, 7 and 9 from the data and failed to identify 
activation of transcription factors Max1 and VDR, while additional prior knowledge 
helped modified Bayesian Decomposition to assign expression patterns to genes that 
were confirmed to contribute to the statistical power of found results. Thus, 
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enhancements done to Bayesian Decomposition were validated on human microarray 
data and demonstrated to improve significance of received results. 
6.2 Future Studies and Prospects 
Contaminations of sample RNA occurred during microarray experiment resulted 
in only 24 of 53 microarray slides available for analysis. Currently, new experiments 
are performed for the most rejected samples, although due to small size of biopsy 
material it will not be always possible to repeat microarray experiments for all 
contaminated pre-treatment samples. When available, new data will be combined 
with the data described in this study and the data mining process will be repeated for 
the full data set. With the increase number of pre- and post- treatment pairs for the 
same patients it will be possible to create new data sets that will allow eliminate inter 
patient variations. 
Our study shows that from 558 human genes reported in TRANSFAC database 
to have a transcription factor, 37% have only one associated transcription factor. With 
majority of genes being regulated by multiple transcription factors, the future of 
microarray data processing is for pattern recognition methods that allow assignment 
of a gene to multiple expression patterns compared to clustering algorithms. 
TRANSFAC database is regularly updated with more annotations, giving more 
prior information. Therefore, using modified Bayesian Decomposition with included 
prior knowledge about groups of co-expressed genes will be even more favorable. On 
the other hand, enhancement analysis of gene groups received by a pattern 
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recognition algorithm will receive more power to draw conclusions about 
transcription factor activity linked to a certain pattern of expression. 
Finally, constantly growing information about genes’ transcription factors 
results in increase of information to interpret at final stages of analysis in order to 
infer activities of upstream signalling pathways. With tens and hundreds of 
downstream indicators of activity of signalling pathways, it is apparent that such an 
analysis needs additional tools to make it possible.  
6.3 Global Picture 
Designed data mining process presented in this study allows recovering 
underlying expression patterns from observed expression profiles and group genes 
together. Biological processes can be mapped to these patterns by performing gene 
group enhancement analysis or directly from the expression pattern behavior. Such 
interpretation is especially effective, since BD accounts for ability of one gene to be 
involved in multiple biological processes. Also, inclusion of prior knowledge into the 
analysis contributes greatly to the strength of the algorithm. 
Determining if a biological process activated or deactivated is a very important 
for analysis of microarray data because of inability to receive direct measurements of 
genes activity. That is, mRNA levels, which microarrays measure, provide only 
downstream indications of cell processes, but can be used to determine mechanisms 
of regulation and activations of signalling pathways that resulted in observed mRNA 
expression data. The problem of protein activity should be solved in the future with 
the further development of proteomics, but microarrays are presently the only truly 
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global measurements tool in functional genomics and reported data analysis process, 
which includes modified Bayesian Decomposition and Automated Sequence 
Annotation Pipeline, provides a great tool for analysis of microarray data. 
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